

Variants in the SOX9 transactivation middle domain induce axial skeleton dysplasia and scoliosis

Lianlei Wang^{1,2,3#}, Zhaoyang Liu^{4#*}, Sen Zhao^{1,3#}, Kexin Xu^{1,3,6#}, Valeria Aceves⁵, Cheng Qiu², Benjamin Troutwine⁵, Lian Liu^{1,3}, Samuel Ma⁵, Yuchen Niu^{3,6,7}, Shengru Wang^{1,3,6}, Suomao Yuan², Xiaoxin Li^{3,6,7}, Lina Zhao^{3,6,7}, Xinyu Liu², Zhihong Wu^{3,6,7}, Terry Jianguo Zhang^{1,3,6*}, Ryan S. Gray^{5*}, and Nan Wu^{1,3,6*}

1. Department of Orthopedic Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, and Chinese Academy of Medical Sciences, Beijing, China.
2. Department of Orthopedic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
3. Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Beijing, China.
4. Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA; Department of Nutritional Sciences, Dell Pediatric Research Institute, University of Texas at Austin, Austin, TX, USA.
5. Department of Nutritional Sciences, Dell Pediatric Research Institute, The University of Texas at Austin, Dell Medical School, Austin, TX, USA.
6. Key laboratory of big data for spinal deformities, Chinese Academy of Medical Sciences, Beijing, China.
7. Medical Research Center, Peking Union Medical College Hospital, Peking Union Medical College, and Chinese Academy of Medical Sciences, Beijing, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 # These authors contributed equally to this work.

26

27 ***Authors for correspondence**

28 Nan Wu

29 No. 1 Shuaifuyuan, Beijing 100730, China

30 Phone: 86-10-69151108, dr.wunan@pumch.cn

31

32 Ryan S. Gray

33 1400 Barbara Jordan Blvd., Austin, TX 78723, USA

34 Phone: 512-495-5052, ryan.gray@austin.utexas.edu

35

36 Terry Jianguo Zhang

37 No. 1 Shuaifuyuan, Beijing 100730, China

38 Phone: 86-10-69151108, jgzhang_pumch@yahoo.com

39

40 Zhaoyang Liu

41 2250 Alcazar Street, Los Angeles, CA 90033, USA

42 Phone: 323-442-2549, liuzhaoy@usc.edu

43

44 **Conflicts of interest**

45 The authors have declared that no conflict of interest exists.

46 ABSTRACT

47 SOX9 is an essential transcriptional regulator of cartilage development and homeostasis. In
48 humans, dysregulation of *SOX9* is associated with a wide spectrum of skeletal disorders,
49 including campomelic and acampomelic dysplasia, and scoliosis. The mechanism of how *SOX9*
50 variants contribute to the spectrum of axial skeletal disorders is not well understood. Here, we
51 report four novel pathogenic variants of *SOX9* identified in a large cohort of patients with
52 congenital vertebral malformations. Three of these heterozygous variants are in the HMG and
53 DIM domains, and for the first time, we report a pathogenic variant within the transactivation
54 middle (TAM) domain of *SOX9*. Probands with these variants exhibit variable skeletal
55 dysplasia, ranging from isolated vertebral malformation to acampomelic dysplasia. We also
56 generated a *Sox9* hypomorphic mutant mouse model bearing a microdeletion within the TAM
57 domain (*Sox9^{Asp272del}*). We demonstrated that disturbance of the TAM domain with missense
58 mutation or microdeletion results in reduced protein stability but does not affect the
59 transcriptional activity of SOX9. Homozygous *Sox9^{Asp272del}* mice exhibited axial skeletal
60 dysplasia including kinked tails, ribcage anomalies, and scoliosis, recapitulating phenotypes
61 observed in human, while heterozygous mutants display a milder phenotype. Analysis of
62 primary chondrocytes and the intervertebral discs in *Sox9^{Asp272del}* mutant mice revealed
63 dysregulation of a panel of genes with major contributions of the extracellular matrix,
64 angiogenesis, and ossification-related processes. In summary, our work identified the first
65 pathologic variant of *SOX9* within the TAM domain and demonstrated that this variant is
66 associated with reduced SOX9 protein stability. Our finding suggests that reduced SOX9
67 stability caused by variants in the TAM domain may be responsible for the milder forms of
68 axial skeleton dysplasia in humans.

69 **Keywords:** *SOX9* (*SRY-Box 9*), Campomelic Dysplasia, Skeletal Dysplasia, Congenital
70 Vertebral Malformations, Scoliosis, Protein Stability
71

72 INTRODUCTION

73 *SRY-Box 9 (SOX9)* encodes a transcriptional regulator essential for the development and
74 homeostasis of cartilaginous tissues (1). SOX9 is required to secure the commitment of
75 skeletogenic progenitor cells to the chondrocyte lineage and direct the formation of multiple
76 elements of the axial and appendicular skeleton (2). Ablation of *Sox9* in mesenchymal
77 progenitors of the limb bud or during the early stages of chondrogenesis results in a complete
78 failure of cartilage and bone generation or severe chondrodysplasia (3). SOX9 is also required
79 for axial skeletogenesis. Deletion of *Sox9* in the notochord prevents the formation of its
80 cartilage-rich perinotochordal sheath and results in notochordal cell death (4). Conditional
81 inactivation of *Sox9* in the *Scx+ / Sox9+* cell populations cause severe hypoplasia of the ribcage
82 and sternum and defective formation of the vertebral bodies and intervertebral discs of the spine
83 (5). Recent studies also demonstrate that *SOX9* plays a crucial role in maintaining the
84 homeostasis of postnatal intervertebral discs (6, 7). These studies affirm that *SOX9* is critical
85 in vertebral column development and maintenance.

86 *SOX9* is featured with a highly conserved SRY-related high-mobility-group-box
87 (HMGbox) DNA-binding domain, which is found in all SOX family proteins that act as
88 transcriptional regulators in cell fate determination and differentiation in a variety of lineages
89 (2, 8). Two molecules of SOX9 can form homodimer via the self-dimerization domain (DIM)
90 upon binding in the minor groove of a DNA sequence composed of two SOX recognition motifs,
91 oriented head-to-head and separated by 3-4 nucleotides (9). In addition to the N-terminal HMG
92 and DIM domains, SOX9 is also composed of three additional domains: the transactivation
93 domain in the middle of the protein (TAM), the transactivation domain at the C-terminal (TAC),
94 and the PQA (Proline, Glutamine, and Alanine-rich) domain (8). In vitro analyses show that
95 TAM and TAC domains can work independently and synergistically to control the

96 transactivation of SOX9 (8). PQA domain has no major role in SOX9 transactivation but may
97 help mediate SOX9 activity in specific contexts (8, 10). The molecular functions of these C-
98 terminal domains are proposed to provide synergistic binding of transcriptional co-activators
99 and basal transcriptional machinery (8). For instance, the CREB (cAMP response element-
100 binding protein) transcription factor can be co-immunoprecipitated using the C-terminal
101 transactivation domains but not with the N-terminal domains of SOX9 (11).

102 Variants in *SOX9* are associated with a range of skeletal deformities including campomelic
103 dysplasia (CMPD, OMIM 114290), acampomelic dysplasia (acampomelic CMPD), and
104 scoliosis (1, 12-15). Heterozygous point mutations (missense, nonsense, frameshift, and splice
105 site) in *SOX9* cause CMPD, characterized by congenital shortening and bending of long bones,
106 vertebral malformation, rib anomalies, dysplasia of scapula, and dysmorphic facial features (14,
107 16-22). Heterozygous *Sox9* knockout mice phenocopy most of the skeletal abnormalities of this
108 syndrome (23). Though it is generally believed that haploinsufficiency for *SOX9* can underlie
109 CMPD, a recent study implicates that combined haploinsufficiency/hypomorphic and
110 dominant-negative mechanisms can apply for some *SOX9* CMPD mutations in a target gene and
111 cell context-dependent manner (24). Roughly 10% of CMPD patients who do not display
112 bending of long bones are subclassified as acampomelic CMPD (25, 26). Many of the *SOX9*
113 variants causing CMPD are located in DIM and HMG domains, which are essential for the
114 dimerization and DNA binding properties of the SOX9 protein (19, 27) and SOX9-dependent
115 regulation of genes such as *Col2a1* (28, 29) and *Coll1a2* (30). These patients usually exhibit
116 severe skeletal abnormalities, including deformities of the long tubular bones, and some of them
117 may present with sex reversal. CMPD can also arise from variants in the TAC and PQA domains
118 of SOX9 (31, 32). Frameshift and nonsense mutations reported in these domains usually result
119 in a truncated SOX9 protein and severe CMPD and sex reversal (32, 33). On the other hand,
120 patients with acampomelic CMPD are more likely to have missense variants, genomic

121 rearrangement with breakpoints upstream of *SOX9*, or a *SOX9* upstream deletion (34). We have
122 previously identified a recurrent missense variant at the prolines/glutamines/serines (PQS)
123 domain (now called TAC domain) of *SOX9* in patients with congenital vertebral malformations
124 but without other systematic deformities (35), which is one of the first non-truncating variants
125 reported in the TAC domain that is associated with a milder form of axial skeleton dysplasia.
126 No missense or nonsense variant in the TAM (previously called K2) domain has been reported
127 so far (36, 37). These observations suggest that locations of variants in different domains of
128 *SOX9* might underline a spectrum of skeletal dysplasia from CMPD to milder forms that
129 primarily or exclusively affect the axial skeleton.

130 To this end, we investigated ultra-rare *SOX9* variants within a large cohort of congenital
131 vertebral malformations and identified four novel variants of *SOX9*. We report the first
132 pathologic missense variant of *SOX9* within the TAM domain associated with a milder form of
133 axial skeletal dysplasia and demonstrated that variants in the TAM domains result in reduced
134 *SOX9* protein stability. We also generated a *Sox9* hypomorphic mouse model with in-frame
135 microdeletion in the TAM domain which recapitulates some of the skeletal phenotypes
136 observed in the human patient. This work enhances our understanding of *SOX9* function in the
137 axial skeleton and provides new insights into the roles of different *SOX9* domains in the
138 spectrum of skeletal dysplasia.


139 RESULTS

140 Rare and *de novo* *SOX9* variants identified in individuals with various severity of skeletal 141 dysplasia

142 We investigated ultra-rare *SOX9* variants with a cohort of 424 patients of congenital vertebral
143 malformations, which consists of a broad spectrum of syndromic and non-syndromic vertebral
144 deformities. Four novel heterozygous missense variants were identified from four probands,
145 including three *de novo* variants (c.218T>C, p.Ile73Thr; c.337A>C, p.Met113Leu and
146 c.826G>T, p.Gly276Cys) and one variant (c.398C>G, p.Ala133Gly) with unknown inheritance
147 (Figure 1, A and B, and Table 1). The clinical and genetic features of these probands are
148 summarized in Table 1. No pathogenic variants in other genes were identified. Family history
149 assessments of the probands show that their parents and siblings are all uneventful.

150 Two of the four probands RDD2003P0397 (Figure 1B) and SCO2003P0412 (Figure 1C)
151 exhibited deformities consistent with the clinical manifestations of acampomelic CMPD.
152 RDD2003P0397 presented congenital vertebral malformation caused by the fusion of the
153 cervical vertebra (Figure 1B). Exome sequencing identified a *de novo* heterozygous missense
154 variant c.337A>C (p.Met113Leu) located within the HMG-box of *SOX9* (Figure 1A). Two
155 missense variants (Met113Thr and Met113Val) that affect the same amino acid have been
156 reported previously in a CMPD patient (Met113Thr) and an acampomelic CMPD patient
157 (Met113Val), respectively (38, 39). SCO2003P0412 presented congenital kyphosis (Figure
158 1C). He had a heterozygous missense variant (c.398C>G, p.Ala133Gly) within the HMG-box
159 of *SOX9* with an unknown inheritance origin (Figure 1C). No pathogenic variant of this amino
160 acid has been reported previously. Notably, Ala133Gly is predicted to be highly deleterious
161 (combined annotation dependent depletion [CADD] score = 24.1).

162



163

Figure 1. Identification of *de novo* or sporadic *SOX9* variants in four individuals with skeletal dysplasia. (A)
 A schematic presentation of the *SOX9* protein. *SOX9* variants identified in this study (green dots), previous studies (orange dots), and the homologs of the mouse variant generated in this study (the red dot) are labeled. (B-E) Sanger sequencing results of *de novo SOX9* variants in three trio families and one sporadic case. (F) Clinical presentation of the four individuals carrying the *SOX9* variants. Red arrows indicate skeletal malformations. G. Both the Asp272 and Gly276 variants are highly conserved residues. *CMPD*: *Campomelic Dysplasia*; *acampomelic CMPD*: *Acampomelic Dysplasia*; *DIM*: dimerization domain; *HMG*: high mobility group domain; *TAM*: transactivation middle, *PQA*: proline, glutamine, and alanine-rich domain; *TAC*: transactivation C-terminal.

173

In contrast to these two cases diagnosed as acampomelic CMPD, the third proband SCO2003P0060 presented a milder skeletal dysplasia phenotype characterized by a wedged vertebra at T6 and thoracic scoliosis (Figure 1D). She also presented with short stature and kyphoscoliosis (Table 1). She carried a *de novo* variant c.218T>C (Ile73Thr) located in the

178 DIM domain of *SOX9* (Figure 1A). A variant affecting the same amino acid (Ile73Asn) has
179 been reported previously in a patient with multiple congenital anomalies (40). This c.218T>C
180 (Ile73Thr) variant has not been included in the gnomAD (v2.1.1, <https://gnomad.broadinstitute.org>,
181 accessed on January 5, 2023), and it is classified as likely pathogenic
182 (PM2_Supporting + PS3_Supporting + PS2 + PM5_Supporting) according to the ACMG
183 guideline (41).

184 In the fourth proband (SCO2003P1898), we identified a *de novo* variant c.826G>T
185 (Gly276Cys) located at the TAM domain (8) of *SOX9* (Figure 1A). This Gly276 residual is
186 highly conserved among vertebrate orthologues (Figure 1G). To our knowledge, this is the first
187 missense mutation reported within the TAM domain in humans. This proband exhibited fused
188 vertebrae from T6-T11 and spinal bifida occulta of L4-L5 (Figure 1E). She also exhibited
189 thoracic scoliosis and clinodactyly of the distal 5th phalange (Figure 1E). Interestingly, the
190 multiple fusion of thoracic vertebrae phenotype in this proband was distinct from the other
191 three patients and the classical CMPD/ acampomelic CMPD patients, suggesting that variants
192 in the TAM domain of *SOX9* may be associated with a distinct type of skeletal anomalies.

193 To further characterize the impact of *SOX9* variants, we modeled the potential structural
194 effects of these mutations predicted by Alpha Fold (Supplemental Figure 1,
195 <https://alphafold.ebi.ac.uk>) (42). The evolutionally conserved *SOX9* Ile73, Met113, and Ala133
196 residues are predicted to help stabilize alpha-helical regions (Supplemental Figure 1, B-D)
197 within the regions with high confidence of prediction or within areas where structural
198 information was empirically determined (unpublished PDB data: 4EUW and 4S2Q). The
199 highly conserved *SOX9* Gly276 residue (Fig. 1G) is predicted to hydrogen bond interact with
200 Asp274 (Supplemental Figure 1E) in a putative helical region of the protein. Altogether, the *in*
201 *silico* evidence showed that the affected residues are highly conserved among vertebrate
202 orthologues, and alteration of these residues may lead to compromised protein structure and

203 altered interactions with other residues, which may jeopardize the function and structural
204 stability of the SOX9 protein.

205 **Effects of the *SOX9* variants on DNA-binding and transcriptional activities of SOX9**

206 Next, we sought to understand how *SOX9* variants affect the DNA-binding and transcriptional
207 activities of the SOX9 protein using electrophoretic mobility shift assay (EMSA) and luciferase
208 reporter assay. We synthesized two sets of EMSA probes derived from the enhancer region of
209 the mouse *Coll1a2* gene (30). Each probe contains a canonical SOX9 DNA-binding motif and
210 was named *Coll1a2* B/C and *Coll1a2* D/E respectively. An equal amount of SOX9 wild-type
211 and variants proteins were incubated with these probe sets for EMSA analyses (Supplemental
212 Figure 2). We discovered that both *SOX9* variants within the HMG-box (Met113Leu and
213 Ala133Gly) display impaired DNA-binding

220




Figure 2. Effects of the *SOX9* variants on DNA-binding and transcriptional activities of *SOX9*. (A) Electrophoretic mobility shift assay (EMSA) was performed on the whole cell lysate extracted from Cos-7 cells. Cell lysate with no transfection was used as a blank control (Blank). Cos-7 cells transfected with a GFP control construct were used as a mock control (Control). The 150-fold unlabeled DNA probes (150X) were incubated with cell lysate of Cos-7 cells transfected with wild-type *SOX9* protein. Free probes were detected at the bottom of the gel.

226 The bound dimer and monomer SOX9 proteins are indicated with black and red arrows, respectively. **(B)**
227 Luciferase assay was performed on wild-type (WT) SOX9 protein and various SOX9 variant mutant proteins
228 using a *Coll1a2*-Luc construct. His165Tyr variant protein was used as a negative control (31). *The statistical*
229 *difference is evaluated by one-way ANOVA followed by Tukey's multiple comparison test. The data are the mean*
230 *of n = 3 independent experiments. Error bars show one standard deviation. * p<0.05 ** p<0.01 ns: not*
231 *significant.*

232 capability characterized by decreased probe binding signal (Figure 2A, black arrows). The
233 *SOX9* variant within the DIM domain (Ile73Thr), which is an essential domain for the
234 dimerization of SOX9 proteins (43), showed reduced DNA-binding capability and loss of
235 dimerization (Figure 2A, black arrows, and red arrows). To define if these variants affected
236 SOX9-dependent gene transcription, we co-transfected various SOX9-expression vectors with
237 a luciferase reporter construct (named *Coll1a2*-Luc) which contains 4 tandem copies of the
238 canonical SOX9 DNA-binding motif *Coll1a2* D/E (Supplemental Figure 3 and Supplemental
239 Table 2) (30, 44). We showed that both the HMG-box variants (Met113Leu and Ala133Gly)
240 and the DIM domain variant (Ile73Thr) exhibited decreased transcriptional activity of SOX9
241 (Figure 2B). In contrast, the variant in the TAM domain (Gly276Cys) did not obviously
242 compromise the transcriptional activity of SOX9 compared with the wild-type protein but
243 showed significantly higher transcriptional activity compared with the Ile73Thr, Met113Leu,
244 and Ala133Gly variants (Figure 2B). Taken together, these data suggest that the variants in
245 HMG and DIM domains are likely affecting the DNA-binding capabilities and homotypic
246 interactions of SOX9, which may lead to compromised SOX9-dependent transcriptional
247 activities. In contrast, variants in the TAM domain may still allow for some transcriptional
248 activity at the canonical SOX9 targets thus permitting partial SOX9-dependent function.


249 **A TAM domain mutation in mice leads to dose-dependent reductions of SOX9**

250 **expression and tail kinking during perinatal development**

251 To further our understanding of the role of the TAM domain variant in skeletal dysplasia, we
252 set out to use a CRISPR-Cas9 gene-editing approach to knock in the human variant Gly276Cys
253 in the mouse (Figure 1E). After multiple injections, we isolated only three CRISPR-injected
254 mice as adults (0.3%; n=123 implanted), likely due to haploinsufficient lethality of *Sox9* in the
255 mouse (23). Serendipitously, we obtained an in-frame microdeletion allele (*Sox9^{em1Rgray}*),
256 which deleted Asp272 (Asp272del), four amino acids upstream of Gly276Cys within the TAM
257 domain (Figure 1A, Figure 3, A and N). Like the Gly276 residual, the Asp272 residual is also
258 highly conserved among vertebrate orthologues (Figure 1G) and is predicted to hydrogen bond
259 interact with Asp274 by Alpha Fold structural prediction (Supplemental Figure 1E). Intercross
260 of these *Sox9^{Asp272del/+}* mice (hereafter called *Sox9^{del}*) generated *Sox9^{del/del}* mutant mice at
261 Mendelian ratios that are indistinguishable from the *Sox9^{del/+}* or wild-type (*Sox9^{+/+}*) littermates
262 at birth. However, by postnatal (P) day 5 *Sox9^{del/del}* mutant mice exhibited a fully penetrant
263 kinked tail phenotype (100%, n=12) (Figure 3D, red arrow). In contrast, heterozygous *Sox9^{del/+}*
264 and wild-type littermates uniformly displayed normal tails (Figure 3, B and C).

265

266



255

Figure 3. A TAM domain mutation in mice leads to dose-dependent reductions of SOX9 expression and tail kinking during perinatal development. (A) Illustration of the in-frame deletion of Asp272 in the Sox9^{del/del} mutant mouse. The red arrow indicates the Asp272del mutation. (B-D) At P5, an obvious kinked tail phenotype was observed in 100% of the Sox9^{del/del} mutant mice, but not in heterozygous Sox9^{del/+} or wild-type littermates.

260 (n=12 for *Sox9^{del/del}* mice, n=8 for *Sox9^{del/+}* and wild-type littermates). (E-G'') Alcian Blue Hematoxylin /Orange
261 G (ABH/OG) staining performed on P5 mouse tail sections revealed normal segmentation of the vertebral bodies
262 and typical proteoglycan staining of IVD and growth plate in *Sox9^{del/del}* mutant mice (G) compared with the
263 wildtype (E) and *Sox9^{del/+}* (F) littermates. Red and pink arrowheads indicate wedged and unwedged IVDs in
264 *Sox9^{del/del}* mutant mouse, respectively. Higher magnification images of the endplate and growth plate and the
265 annulus fibrosus are shown in (E'-G') and (E''-G''). The endplate is indicated with a dotted line and a vertical
266 bar in (E'G'). The boundary between inner and outer annulus fibrosus is indicated with a dotted line in (E''-G'').
267 (n=4 for each genotype). (H-J'') Immunohistochemistry (IHC) analyses of SOX9 performed on P5 mouse tail
268 sections. Higher magnification images of the endplate and growth plate and the annulus fibrosus are shown in
269 (H'-J') and (H''-J''). The endplate is indicated with a dotted line and a vertical bar in (H'-J'). SOX9 expression
270 in proliferative growth plates is indicated with red arrows in (H') and (I'). The boundary between inner and outer
271 annulus fibrosus is indicated with a dot-line in (H''-J''). The absence of SOX9 expression in the outer annulus
272 fibrosus is indicated with red arrows in (J'') and (J'''). (n=4 for each genotype.) (K-M) Immunofluorescence (IF)
273 analyses of SOX9 were performed on P5 mouse tail sections. (n=6 for each genotype.) (N) Sanger sequencing
274 results of wild-type, *Sox9^{del/+}*, and *Sox9^{del/del}* mice. The red arrow indicates the Asp272del mutation. (O-T)
275 Quantification of the number of cell layers in endplate (O), and quantification of the percentile of SOX9 (+) cells
276 in endplate (P), proliferative growth plate (Q), hypertrophic growth plate (R), inner annulus fibrosus (S), and
277 outer annulus fibrosus (T) in three genotypes of mice. Bars are plotted with mean and 95%CI. Each dot represents
278 one mouse analyzed. The statistical difference is evaluated by one-way ANOVA followed by Tukey's multiple
279 comparison test. * p<0.05, ** p<0.01, ***p<0.001. ns: not significant. For (O), n=5 for each genotype; for (PT),
280 n=3 for each genotype. Scale bars: 10mm in B; 100µm in E-E'', H-H'' and K. VB: vertebral body; AF: annulus
281 fibrosus; EP: endplate; GP: growth plate; NP: nucleus pulposus; GP-p: proliferative growth plate; GPh:
282 hypertrophic growth plate; AF-i: inner annulus fibrosus; AF-o: outer annulus fibrosus.

283

284 Many congenital vertebral malformations are due to patterning defects of embryonic
285 somites which contribute to the formation of vertebral bodies and intervertebral discs (IVDs)
286 (45). Histological analysis of *Sox9^{del/del}* mutant mouse tails at P5 revealed normal segmentation
287 and ossification of the vertebral bodies and typical proteoglycan staining in the IVDs and growth
288 plates (Figure 3, E-G). However, the *Sox9^{del/del}* mice showed wedging of the IVDs in regions of
289 tail kinking, a shift of the nucleus pulposus toward the convex side (Figure 3G, red arrowheads),
290 and compression of annulus fibrosus on the concave side of the curvature (Figure 3G''). In
291 contrast, unwedged IVDs adjacent to severe curvatures could display comparably normal
292 structures (Figure 3G, pink arrowhead, and Supplemental Figure 4A). Detailed analysis of the

293 tail sections revealed that the thickness of the cartilaginous endplate of the IVDs is reduced in
294 *Sox9^{del/+}* and the *Sox9^{del/del}* mutant mice compared with that of the wild-type mice (Figure 3, E'
295 and G', yellow bars) quantified by the number of cell layers within the endplate (Figure 3O).
296 The number of endplate cell layers in the unwedged IVDs of the *Sox9^{del/del}* mutant mice is
297 slightly increased compared with that of the wedged IVDs but is still reduced in comparison
298 with the wild-type mice (Figure 3O and Supplemental Figure 4A').

299 We next sought to determine how SOX9 expression was affected in *Sox9^{del/del}* mutant
300 tissues. Immunohistochemistry (IHC) and immunofluorescence (IF) analyses of P5 tail sections
301 revealed that SOX9 expression is regionally reduced in the *Sox9^{del/+}* and the *Sox9^{del/del}* mutant
302 mice (Figure 3, H'-J' and K-M). We observed a decreased SOX9 expression in the proliferative
303 growth plate adjacent to the wedged IVDs but not the unwedged IVDs of the *Sox9^{del/del}* mutant
304 mice (Figure 3, H'-J' and Q, and Supplemental Figure 4, B-B'). No difference in SOX9
305 expression was observed in the hypertrophic growth plate (Figure 3, H'-J' and R) nor the
306 endplate (Figure 3P) among the three genotypes. We also observed reduced expression of
307 SOX9 in both inner and outer layers of the annulus fibrosus of the *Sox9^{del/del}* mutant mice in
308 both wedged and unwedged IVDs (Figure 3, H''-H''' and 3S-T, and Supplemental Figure
309 4B''), with more pronounced effects on the outer layers (Figure 3, J''-J''', red arrows; and
310 Figure 3T), as well as decreased *SOX9* expression in the outer annulus fibrosus of the *Sox9^{del/+}*
311 mice (Figure 3T). IHC analyses of type II collagen (COLII) and type X collagen (COLX)
312 showed a comparable pattern of staining at this age among all three genotypes (Supplemental
313 Figure 4, C-H). All these results suggest that the mutation in the TAM domain leads to a dose-
314 dependent mild reduction of SOX9 expression in various compartments of the spinal tissues,
315 associated with a tail kinking phenotype during perinatal development. However, the overall
316 patterning and segmentation of the vertebral bodies are not affected.


317 ***Sox9*^{Asp272del} is a hypomorphic loss-of-function allele**

318 The tail kinking phenotype and the reduced SOX9 expression in the *Sox9*^{del/+} and the *Sox9*^{del/del}
319 mutant mice are dose-dependent and region-specific, suggesting that the Asp272del
320 microdeletion was behaving as a mild hypomorphic allele of *Sox9*. To test the nature of the
321 *Sox9*^{del} allele, we assessed how skeletal development would be affected when the *Sox9*^{del} allele
322 was *in trans* with an established floxed null allele of *Sox9* (*Sox9*^{lox}) (3). Previous studies show
323 that completely inactivating *Sox9* in osteochondral progenitors using the *Col2a1-Cre* deleter
324 strain (*Col2a1-Cre;Sox9*^{lox/lox}) resulted in embryonic lethality and severe chondrodysplasia in
325 mutant embryos, while the heterozygous recombination of *Sox9* (*Col2a1-Cre;Sox9*^{lox/+}) caused
326 perinatal lethality around P10 displaying dwarfism and kyphosis of the axial skeleton (3).
327 Given these findings, we set out to assess skeletogenesis of the *Col2a1-Cre;Sox9*^{lox/del}
328 compound heterozygous mutants in comparison with the *Col2a1-Cre;Sox9*^{lox/+} heterozygous
329 mutants at P1.

330 The *Col2a1-Cre;Sox9*^{lox/del} compound heterozygous mice were born at Mendelian ratio
331 (n=8; total 67 pups) with a 63% survival rate at P1. Skeletal preparations showed increased
332 defects of craniofacial and ribcage development and bending of the long bone in the *Col2a1-*
333 *Cre;Sox9*^{lox/del} compound heterozygous mutants compared with the *Col2a1-Cre;Sox9*^{lox/+}
334 heterozygous littermates (Supplemental Figure 5, B and C). To better quantify skeletal
335 phenotypes, we analyzed the skull morphology with MicroCT imaging (Figure 4 and
336 Supplemental Figure 5, D-F). We observed decreased skull size in *Col2a1-Cre;Sox9*^{lox/del}
337 compound heterozygous mutants (Figure 4, C-D) compared with Cre (-) controls (Figure 4, A
338 and A') and *Col2a1-Cre;Sox9*^{lox/+} heterozygous mutants (Figure 4, B and B'). However, we
339 observed no significant change in the percentage of bone volume when normalized to total
340 tissue volume (BV/TV) (Figure 4E), which is consistent with the previous report that *Sox9*
341 deletion does not obviously affect osteoblast differentiation (3). Taken together, these genetic

342 studies provide functional evidence that the *Sox9^{del}* allele, which disturbs the TAM domain of
343 *SOX9*, is acting as a mild hypomorphic allele.

344



345

346 **Figure 4. *Sox9*^{Asp272del} is a hypomorphic loss-of-function allele.** (A-C'), 3D MicroCT renderings of mouse skulls
 347 from Cre(-) control (A, A'), *Col2a1-Cre;Sox9*^{lox/+} (B, B'), and *Col2a1-Cre;Sox9*^{lox/del} mutant (C, C') mice at P1
 348 in lateral (A-C) or dorsal views (A'-C'). (D) Quantification of bone surface area (μm^2) of the skull shows a
 349 reduced skull size of the *Col2a1-Cre;Sox9*^{lox/del} compound heterozygous mutant mice ($p=0.0428$) compared to
 350 wild-type Cre(-) control mice. (E) Quantification of the percentage of bone volume vs tissue volume (BV/TV)
 351 shows no loss of bone mass density in the skulls of *Col2a1-Cre;Sox9*^{lox/del} mutant mice ($p=0.2972$) compared to
 352 wild-type Cre(-) control mice. Bars are plotted with mean and standard deviation. Each dot represents one mouse
 353 analyzed. The statistical difference is evaluated by one-way ANOVA followed by Tukey's multiple comparison
 354 test. $n=4$ for each genotype. Scale bars 1mm.


355 **Disturbance of the TAM domain of SOX9 results in dose-dependent skeletal dysplasia in** 356 **young adult mice**

357 By postnatal (P) day 60 (P60), *Sox9*^{del/del} mutant mice are adult-viable (Figure 5C). Dorsal X-
 358 ray imaging showed normal segmentation and growth of the spine irrespective of genotype
 359 (Figure 5, C-D). However, *Sox9*^{del/del} mutant mice did display shorter femurs compared with
 360 *Sox9*^{del/+} and the wild-type mice (Figure 5D). We observed loss of the thoracic (T) 13 floating
 361 ribs (100%, $n=18$; 8 male, 10 female) in *Sox9*^{del/del} mice (Figure 5C', red asterisks; and Figure
 362 4E), with the majority of *Sox9*^{del/del} mice (94%) displaying bilateral loss of the T13 floating ribs
 363 (Figure 5E). Notably, 16% of heterozygous *Sox9*^{del/+} mice ($n=25$, 15 males, 10 females) also
 364 displayed loss of either the right or left T13 floating rib (Figure 5C', red asterisk; and Figure
 365 5E). In contrast, we never observed the loss of the T13 floating ribs in wild-type mice ($n=8$, 4
 366 males, 4 females) (Figure 5, A' and E). Sagittal X-ray imaging showed that 43% of *Sox9*^{del/del}

367 mutant mice (n=7, 4 males, 3 females) showed ribcage defects at P60, which was not observed
368 in wildtype (n=4, 2 males, 2 females) or *Sox9^{del/+}* mice (n=8, 5 males, 3 females) (Supplemental
369 Figure 6). Altogether, these results show that an in-frame microdeletion within the TAM
370 domain of SOX9 causes spatially restrictive disruptions in the development of the axial and
371 appendicular skeleton, some of which are hallmarks of acampomelic CMPD including loss of
372 ribs, ribcage defects, and shortened long bones (14, 16).

373 *Sox9^{del/del}* mutant mice also displayed an exacerbated kinked tail phenotype at P60 (Figure
374 5H). MicroCT imaging showed that tail kinks are associated with dysmorphic coccygeal
375 vertebrae (Figure 5, H-H'''), including ectopic bone deposition in the marrow space in
376 *Sox9^{del/del}* mutant mice, bending of the vertebra, and fusion between vertebrae (Figure 5, H'-
377 H''' and I). The bending and fusion of the caudal vertebrae in the *Sox9^{del/del}* mice mimicked
378 some phenotypes observed in the human patient with the Gly276Cys mutation (Figure 1E).
379 Histological analysis of these kinked tail regions in *Sox9^{del/del}* mice showed severe dysplasia of
380 IVDs and growth plate (Figure 5, L-L'). In some regions, the nucleus pulposus was pushed
381 toward the convex side of the curve, embedded within the annulus fibrosus layers (Figure 5L,
382 yellow arrow). Some *Sox9^{del/del}* mice also showed thinning and disruption of IVD endplate,
383 characterized by loss of cellularity and lack of ossification in the endplate (Figure 5L')
384 compared with the normal structure observed in wild-type and *Sox9^{del/+}* mice (Figure 5, J-J'
385 and K-K'). The vertebral growth plate within the kinked tail region is also disrupted, with
386 disorganized cell columns and reduced proteoglycan staining in some regions of the growth
387 plate (Figure 5L'), consistent with the reported reduction in proteoglycan staining in the IVDs
388 of conditional SOX9 loss-of-function mice (6), further supporting our model that *Sox9^{del}* allele
389 behaves as a mild hypomorphic allele. These results demonstrate that a microdeletion variant
390 in the TAM domain of SOX9 is sufficient to cause the progressive onset of skeletal dysplasia

391 characterized by gross histological pathology of the IVDs, bending of the vertebral bodies, and
392 pathological changes of the growth plate.



393

394 **Figure 5. Variants in the TAM domain of SOX9 results in a dose-dependent skeletal dysplasia in adult**
 395 **mouse. (A-C') Dorsal X-ray images of wild-type (A, A'), *Sox9^{del/+}* (B, B'), and *Sox9^{del/del}* mutant mice (C, C')**
 396 **at P60. The presence and loss of T13 floating ribs are indicated with red arrows and red asterisks, respectively. (D)**
 397 **Measurements of the length of the spine (T1-L6) and the long bone (femur) in P60 mice. Bars are plotted with**
 398 **mean and 95%CI. Each dot represents one mouse analyzed. Male animals are marked with blue dots and female**
 399 **animals are marked with pink dots. The statistical analysis is one-way ANOVA followed by Tukey's multiple**
 400 **comparison test. ***p<0.001. ns: not significant. (n=6 for wild-type mice; 3 males, 3 females. n=8 for *Sox9^{del/+}***
 401 **mice; 4 males, 4 females. n=6 for *Sox9^{del/del}* mice; 3 males, 3 females). (E) Quantification of the floating rib**
 402 **phenotype in P60 mice. (n=12 for wild-type mice; 7 males, 5 females. n=25 for *Sox9^{del/+}* mice; 15 males,**
 403 **females. n=18 for *Sox9^{del/del}* mice; 8 males, 10 females). (F-H) MicroCT analyses showing 3D reconstruction of**


404 the straight tails in wild-type (**F**) and *Sox9^{del/+}* (**G**) mice, but kinked tail in *Sox9^{del/del}* mice (**H**) at P60. Demonstrates
405 a dose-dependent increase in attenuating bony matrix deposition in the bone marrow space in the optical sections
406 of *Sox9^{del/+}* and *Sox9^{del/del}* mutant mice (lower panels: G'-G''' and H'-H''' respectively). (**I**) Analysis of percent
407 bone volume (BV)/tissue volume (TV) of the 5-7th coccygeal vertebrae counting from the distal-most tip of the
408 tail showing significant increase in BV/TV (%) in *Sox9^{del/del}* mutant mice ($p < 0.0001$) compared with wild-type
409 control mice. Bars are plotted with mean and SEM. Each dot represents one coccygeal vertebra analyzed. The
410 statistical difference is evaluated by one-way ANOVA followed by Tukey's multiple comparison test. $n=4$ mice
411 for each genotype. (**J-L'**) ABH/OG staining performed on tail sections of P60 wild-type (**I, I'**), *Sox9^{del/+}* (**J, J'**),
412 and *Sox9^{del/del}* (**K, K'**) mice showed severe disruption of IVD in *Sox9^{del/del}* mice tails. The yellow arrow indicates
413 nucleus pulposus tissue into the annulus fibrosus layer and a yellow asterisk indicates disorganization of the
414 annulus fibrosus. $n=3$ for each genotype. *Scale bars: 10mm in A; 5mm in A'; 2mm in F; and 100 μ m in I-I'. AF:*
415 *annulus fibrosus; EP: endplate; GP: growth plate; NP: nucleus pulposus.*

416 **Disturbance of the TAM domain of SOX9 leads to late-onset scoliosis in mouse**

417 We consistently observed skeletal dysplasia in the tails of *Sox9^{del/del}* mutant mice from P5 to
418 P60 but we never observed obvious dysplasia in the thoracic or lumbar spine at this time
419 (Figure 5, A-C). However, when we assessed these mutants at 6 month-of-age, ~ 43% of
420 *Sox9^{del/del}* mutant mice ($n=14$, 8 males, 6 females) displayed mild lateral curvature of the spine
421 reminiscent of late-onset scoliosis (Figure 6, C and F). The severity of spine curvatures,
422 quantified as Cobb angles (46), ranged from 10.2° to 13.8° (Figure 6I). We observed scoliosis
423 in both male and female *Sox9^{del/del}* mutant mice with curvatures in both rightward and leftward
424 directions (Figure 6I). The distribution of the apex of the curvature was enriched in the lower
425 thoracic region (T12-T13) and lumbar region (L1, L4, and L5) (Figure 6J). In comparison, only
426 one female *Sox9^{del/+}* mouse ($n=15$, 12 males, 3 females) showed a mild curve of 10.7° at 6
427 months (Figure 6H), while the majority of *Sox9^{del/+}* mice and all of the wild-type mice ($n=8$, 4
428 males and 4 females) had no measurable scoliosis at 6 months (Figure 6G).

429 In addition, we also observed a range of rib cage deformities in 93% of the *Sox9^{del/del}* mice
430 at 6 months ($n=14$, 8 males, 6 females), from obvious dorsal ward bending of the sternums into
431 the rib cage akin to pectus excavatum in humans (47) (Figure 6F'), to milder bending of the

432 sternums (Supplemental Figure 7, C and D) and curvatures of the distal ribs (Supplemental
433 Figure 7E). We only observed 1 male *Sox9^{del/+}* mice displaying mild bending of the sternum at
434 6 months (n=8, 4 males and 4 females) (Supplemental Figure 7B). In contrast, none of the wild-
435 type littermates displayed rib cage deformities (n=8, 4 males and 4 females) (Figure 6D'). The
436 etiology of pectus excavatum is still not clear, but it may be associated with genetic or
437 connective tissue disease that leads to compromised support of the rib cage (48). These results
438 suggest that disturbance of the TAM domain of *SOX9* also affects the stability of the axial
439 skeleton during adult development, modeling late-onset scoliosis and progressive rib cage
440 deformities in a dose-dependent manner, potentially through regulating the homeostasis of
441 cartilaginous and connective tissues in the spine and rib cage.



450

Figure 6. Adult *Sox9^{del/del}* mutant mice display IVD defects of the spine. (A-F') Representative dorsal X-ray images of wild-type (A, D), *Sox9^{del/+}* (B, E) and *Sox9^{del/del}* mutant mice (C, F) at 6 month-of-age. Sagittal X-ray images of the same mouse are shown in (D'-F'). Red arrows in (C) and (F) indicate scoliosis. The red arrow in

454 F' indicates rib cage deformity. (n=8 for wild-type mice; 4 males, 4 females. n=15 for *Sox9^{del/+}* mice; 12 males, 3
455 females. n=14 for *Sox9^{del/del}* mice; 8 males, 6 females.) (G-I) Cobb angle measurements of wild-type (G), *Sox9^{del/+}*
456 (H) and *Sox9^{del/del}* (I) mice at 6 months. Areas of scoliosis (Cobb angle >10 degrees) are indicated with two red
457 dot lines. (J) Heat map of the apex distribution of the scoliotic *Sox9^{del/del}* mutant mice at 6 months. The heat map
458 is plotted with the axis level of the thoracic spine (T8-L6) and the number of scoliotic mice with apex observed at
459 each level. (n=8 for wild-type mice; 4 males, 4 females. n=15 for *Sox9^{del/+}* mice; 12 males, 3 females. n=14 for
460 *Sox9^{del/del}* mice; 8 males, 6 females.) (K-M'), ABH/OG staining performed on lumbar IVDs (L4/5) of 6-month-
461 old wild-type (K, K'), *Sox9^{del/+}* (L, L') and *Sox9^{del/del}* (M, M') mice. The endplate and growth plate are indicated
462 with black and yellow asterisks, respectively. Endplate clefts observed in *Sox9^{del/del}* mice are indicated with a red
463 arrow in (M') (n=3 for each genotype.) (N-S), Immunohistochemistry (IHC) analyses of type X collagen (COLX)
464 and type II collagen (COLII) in 6-month-old wild-type (N, N' and Q), *Sox9^{del/+}* (O, O' and R) and *Sox9^{del/del}* (P,
465 P' and S) mice. Endplate staining and growth plate staining are indicated with red and yellow asterisks,
466 respectively. n=6 for each genotype. Scale bars: 10mm in A, D, and D'; 100µm in K-K', N-N', and Q. EP:
467 endplate; GP: growth plate; NP: nucleus pulposus.

468

469 **Adult *Sox9^{del/del}* mutant mice display IVD defects of the spine**

470 SOX9 function is required in adult mice to maintain homeostasis of the cartilaginous tissues
471 (6, 49). To determine if *Sox9^{del/del}* mutant mice might accumulate increased pathology of
472 skeletal elements in older mice we looked at 6-month-old cohorts. We observed endplate
473 defects in 50% (n=6) of *Sox9^{del/del}* mutant mice (Figure 6, M-M'), characterized by vertical cleft
474 through endplate into growth plate in the lumbar IVDs (Figure 6M', red arrow), which was not
475 observed in *Sox9^{del/+}* or wild-type littermates (n=6 for each genotype) (Figure 6, K-L'). We also
476 observed reduced proteoglycan staining in some growth plates of the lumbar spine in the
477 *Sox9^{del/del}* mice (Figure 6M', yellow asterisk).


478 The endplates of the lumbar IVDs undergo ossification in wild-type adult mice (Figure 6,
479 K' and 6L', black asterisks, and Supplemental Figure 7, F-G'). Interestingly, the *Sox9^{del/del}* mice
480 consistently displayed a reduction in endplate ossification in lumbar regions (Figure 6M' and
481 Supplemental Figure 7J'), which was associated with an accumulation of COLX (+),
482 hypertrophic chondrocyte-like cells in the endplate (Figure 6P', red asterisk; Figure 6M', black

483 asterisk, and Supplemental Figure 7, H' and I'). COLX is a biomarker of IVD degeneration
484 (50, 51). We also observed increased COLX expression enriched around the endplate cleft and
485 in the growth plate and nucleus pulposus of the *Sox9^{del/del}* mice (Figure 6, P-P'), which suggests
486 that reduction in SOX9 function is eliciting degenerative changes in the IVD. The ossification
487 of the endplate in wild-type and *Sox9^{del/+}* mice was also correlated with a reduction of COLII
488 expression in the endplate (Figure 6, Q and R, red asterisks), however, COLII staining was
489 increased in *Sox9^{del/del}* mutant endplate (Figure 6S, red asterisks). The persistent expression of
490 both COLII (Figure 6S) and COLX (Figure 6P') in large, hypertrophic chondrocyte-like cells
491 in the endplate suggests that the TAM domain of SOX9 is important for pathways involved in
492 chondrocyte maturation in the lumbar spine.

493 **Variants of the TAM domain decrease SOX9 protein stability and chondrogenesis in cell** 494 **culture**

495 Next, we sought to determine how disturbance of the TAM domain affects SOX9 function.
496 Consistent with our previous results with the human Gly276Cys *SOX9* TAM domain variant
497 (Figure 2B), the luciferase assay showed that the Asp272del variant of *SOX9* showed no
498 obvious change in transcriptional activity compared with the wild-type protein or the
499 Gly276Cys variant (Figure 2B). Previous studies reported that phosphorylation of the TAM
500 domain helps regulate SOX9 stability in response to DNA damage in cancer cells (52). We next
501 sought to assay SOX9 protein stability by measuring the half-life of different SOX9 variants in
502 Cos-7 cell culture after treatment with cycloheximide (CHX), which blocks *de novo* protein
503 synthesis (53). Quantification of SOX9 revealed that the half-life of wild-type SOX9 was ~4
504 hours after CHX treatment, while the half-lives of both the human Gly276Cys and the mouse
505 Asp272del variant of SOX9 proteins were reduced to ~2.5 hours (Figure 7, A and B, n=3).

506



507
508
509
510
511
512
513
514

Figure 7. Variants of the TAM domain leads to reduced protein stability of SOX9 and impaired chondrogenesis in cell culture. (A-B) Representative Western blot assay of SOX9 half-life measurements (A). Cos-7 cells were transfected with plasmids expressing wild-type SOX9, the Asp272del variant, or the Gly276Cys variant for 48 hours, followed by cycloheximide (CHX) treatment (80 µg/ml) for 0h, 1h, 2h, 4h, and 6h. Total protein was harvested at each time point and blotted with SOX9. GAPDH was used as a loading control. Quantification of band intensity was shown in (B). (n=3 experiments.) (C-D), Alcian Blue staining (C) on costal chondrocytes isolated from P5 wild-type, *Sox9*^{del/+}, and *Sox9*^{del/del} mice that were matured for 10 days. The

515 number of nodules formed per tissue-culture well was quantified in (D). (n=3 experiments.) (E), Real-time RT-
516 PCR analyses of *Sox9*, *Col2a1*, *Acan*, and *Col10a1* on RNA isolated from P5 primary costal chondrocytes of three
517 different genotypes. Bars are plotted with mean and 95%CI. Three pups of each genotype were pooled to generate
518 a sample. Three technique replicas were applied for each experiment. The statistical difference is evaluated by
519 one-way ANOVA followed by Tukey's multiple comparison test. * p<0.05, **: p<0.01, ***p<0.001.
520 ***p<0.0001. ns: not significant. (F), Immunofluorescence (IF) analyses of SOX9 performed on P5 primary costal
521 chondrocytes of three different genotypes revealed comparable expression levels and normal nuclei localization
522 of the SOX9 Asp272del variant protein. (n=3 experiments.) Scale bars: 500µm in C; 50µm in F.

523 Given the pathology of cartilaginous tissues in the IVD in *Sox9^{del/del}* mutant mice, we next
524 sought to test if primary costal chondrocytes would also model these defects in vitro. Alcian
525 Blue staining on matured primary costal chondrocytes revealed weaker Alcian Blue staining
526 and a reduction in cartilage nodules formation of chondrocytes derived from both *Sox9^{del/+}* and
527 *Sox9^{del/del}* mice compared with that derived from wild-type littermates (Figure 7, C and D),
528 suggesting diminished chondrogenesis in vitro (54) with the Asp272del TAM domain variant
529 of *SOX9*. This observation is confirmed by the reduced expression of *Acan* (Figure. 7E), which
530 encodes the major chondroitin sulfate proteoglycan aggrecan and its deposition is considered a
531 hallmark of chondrogenesis (55). In agreement with our observations of increased COLX
532 expression in cartilaginous endplate in *Sox9^{del/del}* mutant mice (Figure 6, P-P'), we also observed
533 increased *Col10a1* expression in primary costal chondrocyte culture in both *Sox9^{del/+}* and
534 *Sox9^{del/del}* mice (Figure 7E). These findings indicate that the Asp272del TAM domain variant
535 of *SOX9* is driving cell autonomous, precocious hypertrophy signaling in chondrocytes. Similar
536 alterations in gene regulation have been previously observed in the *Sox9* haploinsufficiency
537 mice, where the overall markers of chondrogenesis were inhibited, yet are also coupled with
538 increased expression of markers of hypertrophy and mineralization (23, 56).

539 *Col2a1* is a direct transcriptional target of SOX9 (28), however, *Col2a1* expression was
540 not obviously changed in costal chondrocytes derived from *Sox9^{del/+}* or *Sox9^{del/del}* mice (Figure
541 7E), which is consistent with our analysis of COLII in vivo (Supplemental Figure 4, C-E). We

542 observed increased *Sox9* mRNA level in costal chondrocytes of *Sox9^{del/+}* and *Sox9^{del/del}* mice
543 compared with that in wild-type cells (Figure 7E), likely the result of SOX9 positive feedback
544 on its expression (57). Despite increased *Sox9* transcript levels, we failed to observe any
545 obvious changes in the expression or localization of the SOX9 protein by immunofluorescence
546 or western blotting in primary costal chondrocytes (Figure 7F and Supplemental Figure 8).
547 These results suggest a potential complementation effect driving *Sox9* mRNA overexpression
548 in response to the hypomorphic loss of function of the TAM domain microdeletion in *SOX9*,
549 which was consistent with our previous observations of decreased SOX9 protein stability
550 (Figure 7, A and B).

551 **Disturbance in of the TAM domain of SOX9 generates global transcriptional changes in**
552 **chondrocytes and altered protein expression in spinal tissues**

553 Our results show that variants in the TAM domain of *SOX9* lead to the compromised formation
554 of the intervertebral discs (Figure 3G and Figure 5L), altered ossification in the endplates
555 (Figure 6, M, P and S), and decreased chondrogenesis in cell culture (Figure 7, C-E). All of this
556 data suggests that variants in the TAM domain of *SOX9* have a crucial role in the differentiation
557 and maturation of the cartilage lineages. To better understand how the Asp272del variant
558 affects gene regulation, we performed RNA-sequencing analyses on P5 primary costal
559 chondrocytes, a well-accepted source of primary chondrocytes (58, 59). We observed a total of
560 816 upregulated genes and 452 down-regulated genes in homozygous *Sox9^{del/del}* compared to
561 heterozygous *Sox9^{del/+}* mutant mice (Figure 8A and Supplemental Table 3). Gene Ontology
562 (GO) enrichment analysis revealed that the differentially expressed genes were strongly related
563 to extracellular matrix (GO:0031012), angiogenesis (GO:0001525), and ossification
564 (GO:0001503) (Supplemental Table 4). Other altered biological processes included connective

565 tissue development (GO:0061448), cell-substrate adhesion (GO:0031589), and epithelial cell
566 migration (GO:0010631) (Supplemental Table 4).

567 We observed global alterations in components of the extracellular matrix, including
568 increased expression of *Col8a1* (type VIII collagen), *Eln* (elastin), and *Prg4* (proteoglycan 4),
569 and mild upregulation of *Col10a1* (type X collagen) (Figure 8B), which is consistent with our
570 observations of increased *Col10a1*/COLX expression in vivo (Figure 6, P-P') and in primary
571 chondrocyte culture (Figure 7E). On the contrary, the expression of some fibrotic collagens,
572 including *Col3a1* and *Col4a1* was significantly reduced (Figure 8B). Additional extracellular
573 matrix components, such as *Tnxb* (tenascin-X), *Tnc* (tenascin-C) and *Lama2* (laminin subunit
574 alpha 2) were also down-regulated. In addition, several genes involved in angiogenesis such as
575 *Vegfa* were upregulated. Finally, we observed intriguing results in a class of genes associated
576 with ossification. We found reduced expression of some major markers of ossification,
577 including *Colla1*, *Mmp13*, and *Postn* (periostin, osteoblast specific factor), and increased
578 expression of *Timp3* (tissue inhibitor of metalloproteinase 3) (Figure 8B). These results may
579 explain the progressive, high penetrance (93%) of the rib cage deformities in the *Sox9^{del/del}* mice
580 (Figure 6F'), which may be caused by impaired ossification of the rib cage. This dysregulation
581 of genes important for endochondral ossification is also consistent with the loss of endplate
582 ossification observed within the lumbar IVDs of the *Sox9^{del/del}* mice (Figure 6, M-M'). We also
583 observed increased expression of the bone morphogenetic protein (BMP) and transforming
584 growth factor- β (TGF β) pathways, including *Bmp6*, *Smad5*, and *Tgfbr3*, coupled with up-
585 regulation of some BMP signaling inhibitors, such as *Nog* (Noggin) and *Grem1* (gremlin, 1
586 DAN family BMP antagonist) (Figure 8B). Collectively, these results show large-scale
587 dysregulation of genes that are important for chondrocyte differentiation and ossification in
588 *Sox9^{del/del}* mice.




Figure 8. The Asp272del TAM domain variant of SOX9 generates global transcriptional changes in chondrocytes and altered protein expression in spinal tissues of the IVD. (A) Volcano plot of RNA-sequencing data generated from P5 primary costal chondrocytes, plotted with Log2 (Fold Change) (X axis) and Log10 (padj)(Y axis, padj<0.05). Several top-changed genes were labeled on the plot. (n=3 replicas for each genotype.) **(B), A**

592 list of candidate genes involved in the top three categories of GO term enrichment analyses. **C-H'**,
593 Immunohistochemistry (IHC) analyses of tenascin X (TNX) and type I collagen (COLI) in P5 tail sections of wild-
594 type (**C, C'** and **F, F'**), *Sox9^{del/+}* (**D, D'** and **G, G'**) and *Sox9^{del/del}* (**E, E'** and **H, H'**) mice. TNX expression in
595 connective tissues (red asterisks), inner annulus fibrosus (red arrows), and endplate (yellow arrows) are shown in
596 (**C'**). Loss of TNX expression in connective tissues is indicated with a black asterisk in (**E'**). The presence or loss
597 of COLI staining in annulus fibrosus is indicated with red or black asterisks respectively in (**F'-H'**). (n=6 for each
598 genotype.) **I-K**, Immunofluorescence (IF) analyses of COLI were performed on P5 mouse tail sections of three
599 different genotypes. (n=6 for each genotype.) **L**, A model of how SOX9 regulates axial skeleton homeostasis. In
600 a healthy spine, SOX9 maintains normal expression of TNX and COLI in annulus fibrosus, connective tissues and
601 cartilaginous tissues, and precisely controls the expression of COLX in chondrocytes. However, disturbance of
602 SOX9 function results in reduced expression of TNX and COLI in connective tissues and dysregulated expression
603 of COLX in the endplate and growth plate of the spine, which synergistically results in a range of skeletal
604 dysplasia, including intervertebral disc (IVD) deformity, IVD degeneration, and scoliosis. *Scale bars: 100µm. VB:*
605 *vertebral body; CT: connective tissue; EP: endplate; NP: nucleus pulposus; GP-p: proliferative growth plate;*
606 *GP-h: hypertrophic growth plate; AF-i: inner annulus fibrosus; AF-o: outer annulus fibrosus.*

607

608 In humans, disruption of the *TNXB* gene (which encodes tenascin-X, TNX, an extracellular
609 matrix protein) is associated with Ehlers-Danlos syndrome, which is a connective tissue
610 disorder caused by defective deposition of type I collagen leading to hypermobility of joints
611 and kyphoscoliosis in some patients (60, 61). Since we observed reduced expression of both
612 *Tnxb* and *Coll1a1* in primary chondrocyte cultures prior to the onset of scoliosis, we next set
613 out to assay the expression of TNX and COLI in vivo. IHC analyses on P5 wild-type tail
614 sections showed strong TNX expression in the inner annulus fibrosus (Figure 8, C-C', red
615 arrows), a portion of cells in the endplate (Figure 8C', yellow arrows), and the connective
616 tissues surrounding the annulus fibrosus (Figure 8C', red asterisk). However, the expression of
617 TNX was consistently diminished in both *Sox9^{del/+}* and *Sox9^{del/del}* mice (Figure 8, D' and E'),
618 with only weak staining in the connective tissues adjacent to IVD in the *Sox9^{del/+}* mice (Figure
619 8D', red asterisk). Similarly, IHC and IF analyses revealed robust COLI expression in the entire
620 annulus fibrosus and adjacent connective tissues of the wild-type mice (Figure 8, F-F', red
621 asterisks; and Figure 8I), which is depleted in both *Sox9^{del/+}* and *Sox9^{del/del}* mice (Figure 8, G

622 and H'), with limited expression in the outer annulus fibrosus (Figure 8G', red asterisk; and
623 Figure 8J-K). Interestingly, the diminished expression of TNX and COLI in annulus fibrosus
624 overlaps altered SOX9 expression in annulus fibrosus (Figure 3, H''-J'''), suggesting a
625 regulatory role of SOX9 in maintaining the proper expression of these genes in the IVD.
626 Altogether, this finding suggests that disturbance of the TAM domain allows for normal
627 skeletal development to occur but still results in the loss of components, such as TNX and
628 COLI, that are likely necessary for the maturation and homeostasis of the spine (Figure 8L).

629

630

631 **DISCUSSION**

632 Heterozygous mutations in *SOX9* cause CMPD, a rare, dominant semi-lethal skeletal disease
633 characterized by congenital shortening and bending of long bones. Most of the variants that
634 cause CMPD are non-truncating mutations in HMG and DIM domains or truncating mutations
635 in PQA and TAC domains (31-33). Notably, variants associated with acampomelic CMPD, a
636 subpopulation of CMPD patients that exhibit milder skeletal phenotypes without displaying
637 bending of long bones, are more likely to be either missense mutations of *SOX9* or deletions or
638 rearrangements upstream of the *SOX9* coding region (34, 38). These observations suggest that
639 locations and the nature of the variants may underlie the severity of CMPD/ acampomelic
640 CMPD.

641 We recently reported a non-truncating pathological variant in the TAC domain which is
642 associated with a milder form of axial skeleton dysplasia (35). Here, we reported the first non-
643 truncating pathological variant in the TAM domain of *SOX9*. Patient with this variant exhibit
644 skeletal dysplasia that primarily affects the axial skeleton and is milder than
645 CMPD/acampomelic CMPD. Our studies suggest that non-truncating *SOX9* variants in the
646 middle (TAM) or C-terminal transactivation domains (TAC) of *SOX9* may contribute to
647 skeletal dysplasia that is milder than classic CMPD/acampomelic CMPD, in which they affect
648 primarily or exclusively the axial skeleton. These two studies corroborate with in vitro evidence
649 suggest that the two transactivation domains of *SOX9* can work synergistically to
650 control the function of *SOX9* (8).

651 Though the function of *SOX9* in different skeletal tissues is well studied in mice (23), the
652 molecular, cellular, and developmental abnormalities leading to CMPD/ acampomelic CMPD,
653 especially the milder form of axial skeletal dysplasia, are not well defined, largely due to the
654 lack of human evidence and appropriate animal models (24). In the present study, we analyzed

655 exome sequencing from 424 congenital vertebral malformations cases, a cohort of patients with
656 a broad spectrum of syndromic and non-syndromic vertebral malformations. The inclusion of
657 patients with milder skeletal phenotypes enabled us to identify four novel ultra-rare *SOX9*
658 variants. We demonstrated that these variants were deleterious and provided acampomelic
659 CMPD diagnosis for two of the patients who carry *de novo* variants in the HMG domain of
660 *SOX9*. The identification of these two variants expands the mutational spectrum of *SOX9* in
661 acampomelic CMPD and conforms that the hypomorphic *SOX9* allele that perturbs its DNA
662 binding ability contributes to acampomelic CMPD. Another variant is in the DIM domain and
663 leads to compromised SOX9 dimerization, which is consistent with previous analyses of DIM
664 domain mutations (19).

665 For the first time, we identified a missense mutation, Gly276Cys, in the TAM domain of
666 *SOX9*. The patient carrying this variant exhibited milder phenotypes than that of classical
667 CMPD/ acampomelic CMPD, with multiple fusions of the thoracic vertebral and clinodactyly
668 of the distal 5th phalange. Unlike the three variants identified in HMG and DIM domains, the
669 mutation in the TAM domain does not obviously affect the transcriptional activity of canonical
670 direct SOX9 targets but leads to reduced protein stability of SOX9. A previous study using
671 cancer cells shows that the *SOX9* TAM domain plays an important role in the cellular response
672 to DNA damage. A conserved phosphodegron (CPD) motif locates within the TAM
673 transactivation domain is essential for the binding of FBW7 α to SOX9, which is required for
674 subsequent ubiquitination and proteasomal destruction of the SOX9 protein (52). Our study
675 confirms that TAM domain is also involved in the regulation of SOX9 stability in chondrogenic
676 lineages, however, the mechanisms of how specific amino acid residues in TAM domain
677 regulate the turnover of SOX9 protein warrants further investigation.

678 Since no non-truncating variants in the TAM domain of SOX9 has been previously
679 reported, we engineered a new mice model (*Sox9^{del/del}*) resulting in an in-frame microdeletion

680 of a single amino acid in the TAM domain (Asp272del), which is four residuals upstream of
681 the human variant (Gly276Cys). Though we were not able to generate the exact human
682 mutation, the *Sox9^{del}* allele also provides us with valuable information to understand the role of
683 the TAM domain in *SOX9* function and the etiology of a milder form of axial skeleton
684 dysplasia. *In silico* analyses show that the Asp272 and Gly276 residues are highly conserved
685 among vertebrate orthologues, and both are predicted to hydrogen bond interact with Asp274
686 to stable a putative helical structure of the SOX9 protein. In addition, the Asp272del variant
687 also shows adequate luciferase activity and reduced protein stability that is comparable with
688 the Gly276Cys variant. We further demonstrate that *Sox9^{del}* is a hypomorphic allele with the
689 genetic complementary experiment over a conditional *Sox9* null allele (*Sox9^{fllox}*). These
690 observations suggest that the *Sox9^{del}* allele may serve as a good genetic mouse model to study
691 the function of the TAM domain and the pathogenesis of milder forms of axial skeletal
692 dysplasia.

693 Interestingly, the homozygous *Sox9^{del/del}* mutant mice display axial skeleton phenotypes
694 that phenocopy some of the dysplasia observed in the human patient with the Gly276Cys
695 variant, but not in mouse models with typical null or haploinsufficiency of *Sox9* (3, 23). For
696 example, the *Sox9^{del/del}* mutant mice display bending and fusion of some caudal vertebrae
697 without displaying bending of the long bones. The *Sox9^{del/del}* mutant mice also show loss of
698 T13 floating ribs, rib cage dysmorphologies, pathoses of IVD and growth plates, and late-onset
699 scoliosis without congenital vertebral malformations. In contrast, haploinsufficiency of *Sox9*
700 results in more severe forms of skeletal dysplasia and defective cartilage development (14, 23,
701 38). On the other hand, the *Sox9^{del/+}* mutant mice show much milder skeletal phenotypes
702 compared with *Sox9^{del/del}* and *Sox9* haploinsufficiency mice. All these observations confirm that
703 *Sox9^{del}* is a mild hypomorphic allele with no dominant-negative impact as reported in other
704 *SOX9* truncating variants (24). Though *Sox9^{del}* does not obviously affect the expression of

705 SOX9 protein at the tissue level (Supplemental Figure 8, Western blot of primary chondrocytes)
706 or significantly reduce its transcriptional activity, the function of SOX9 may be compromised
707 by reduced protein stability. Therefore, the hypomorphic *Sox9^{del}* allele may permit some
708 transcriptional activity at the canonical SOX9 targets and allows for normal skeletal
709 development to occur, however, it may lead to compromised tissue development and
710 maintenance during neonatal and adult development, such as reduced proliferation of the
711 endplate in P5 IVD, and reduced proteoglycan staining of the vertebral growth plate in adult
712 mice, which is consistent with the previous finding on the crucial role of SOX9 in disc cell
713 survival and phenotype maintenance, and in the regulation of distinct compartment-specific
714 transcriptomic landscapes (6, 7).

715 Moreover, IHC analysis on tissue sections shows that the expression of SOX9 is reduced
716 in distinct regions of the cartilaginous and connective tissues of the spine (Figure 3, P5 tail).
717 RNA-seq performed on costal chondrocytes at the same age revealed that *Sox9^{del}* mutation
718 causes reduced expression of extracellular matrix components, and alterations in angiogenesis
719 and ossification pathways. SOX9 is known to have a direct role in the establishment of tendon
720 and ligament attachments and indirectly for endochondral ossification (2, 5), thus the role of
721 SOX9 TAM variants on the development and homeostasis of bone and dense connective tissues
722 should be further studied.

723 One possible mechanism of wedged IVD observed in P5 *Sox9^{de/dell}* mice is that the altered
724 extracellular matrix components (e.g. abnormally decreased expression of TNX and COL1)
725 lead to altered biomechanical properties of the disc, while the increased expression of type X
726 collagen and dysregulated ossification process within the vertebrae, probably due to the reduced
727 expression of *Colla1* and *Mmp13* (Figure 8B) and reduced proliferation within the proliferative
728 growth plate (Figure 3Q), synergistically leads to disc deformity (Figure 8L). We also observe
729 signs of disc degeneration in older *Sox9^{de/dell}* mice, including reduced proteoglycan staining and

730 endplate abnormalities. Our study adds support to previous studies showing that SOX9 is
731 essential for spine development and maintenance of the structural integrity of the spine (3, 6,
732 7, 49). Interestingly, we observed a similar endplate phenotype in another genetic mouse model
733 (*Adgrg6* conditional knockout) that was published earlier by our group (62). In *Adgrg6*
734 conditional mutant mice, we suggest that the endplate-oriented phenotype is a secondary effect
735 due to compromised biomechanical properties of the IVD because of altered expression of
736 extracellular matrix components, including reduced expression of SOX9 but increased
737 expression of type X collagen (62, 63). In this study, we observed similar alterations in
738 *Sox9^{del/del}* mice, where we showed SOX9 expression is regionally reduced, increased expression
739 of type X collagen in the endplate and growth plate, supporting a potential synergistic
740 interaction between SOX9 and ADGRG6, which is implicated in adolescent idiopathic scoliosis
741 in humans (64).

742 Taken together, our results demonstrate adult viable skeletal dysplasia phenotypes
743 including scoliosis and malformation of the distal axial skeleton in mice and humans, due to
744 novel pathological mutations localized within the TAM domain of *SOX9*. Disturbance of the
745 *SOX9* TAM domain in mice and in human patient showed axial skeletal malformations without
746 generating more severe skeletal dysplasia and autosomal sex reversal phenotypes, which are
747 commonly associated with known CMPD/ acampomic CMPD *SOX9* mutations in humans.
748 Our study corroborates previous evidence from human and mouse studies that *SOX9* has critical
749 roles in axial skeleton formation and adult homeostasis and that *SOX9* hypomorphic alleles
750 resulting from variants in the TAM or TAC domain likely underlie skeletal dysplasia that is
751 milder than CMPD/ acampomic CMPD, which primarily or exclusively affect the axial
752 skeleton. In conclusion, human and mouse variants in *SOX9* contribute to a range of skeletal
753 dysplasia dependent on the domain/residual affected, which is suggestive of a general
754 mechanism to be further explored in skeletal dysplasia in humans.

755 MATERIALS AND METHODS

756 Human subjects

757 A total of 424 probands with congenital vertebral malformations admitted into Peking Union
758 Medical College Hospital (PUMCH) were consecutively enrolled under the framework of the
759 Deciphering disorders Involving Scoliosis and COmorbidities (DISCO) study
760 (<http://www.discostudy.org/>) from 2009 to 2016. Clinical evaluation and exome sequencing
761 were performed as previously described (65). Raw data were processed using the in-house
762 developed Peking Union Medical College Hospital Pipeline (PUMP) (65, 66). Ultra-rare
763 variants in *SOX9* were selected based on the following criteria: 1) Predicted to alter the protein
764 sequence; 2) Either arising *de novo* or absent from the public databases such as the genome
765 aggregation database (gnomAD, <https://gnomad.broadinstitute.org/>). Patients carrying
766 candidate variants in *SOX9* are reported in this study.

767 Sanger sequencing

768 For human patients and mouse models, candidate variants in *SOX9/Sox9* were validated by
769 Sanger sequencing. For human patients, variant-encoding amplicons were amplified by PCR
770 from genomic DNA obtained from probands and parents from trios (Supplemental Table 1).
771 The amplicons were purified using an Axygen AP-GX-50 kit (lot no. 05915KE1) and
772 sequenced by Sanger sequencing on an ABI3730XL instrument.

773 Construction of *SOX9* expression constructs and Cos-7 cell culture

774 Full-length wild-type *SOX9* and *SOX9* with variants were cloned into the pEGFP-C1 expression
775 vector (Catalog #6084-1, Takara Bio Company). Cos-7 cells were obtained from the Institute
776 of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). The cells

777 were cultured in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (Gibco),
778 penicillin (50 U/ml, Life Technology), and streptomycin (50 µg/ml, Life Technology).

779 **Electrophoretic mobility shift assay**

780 Electrophoretic mobility shift assay (EMSA) was used to detect the binding affinity of SOX9
781 proteins to the conical SOX9 binding motifs as previously described with modifications (19).
782 Biotin-labeled DNA probes were designed based on two canonical SOX9 binding motifs
783 derived from an enhancer region of the mouse *Col11a2* gene, named *Col11a2* B/C and D/E
784 respectively, according to the original publication (19). The sequences of these motifs are listed
785 in Supplemental Table 2. Cos-7 cells were transfected with the SOX9 expression constructs or
786 GFP control construct for 48 hours. The expression level of wild-type and various SOX9
787 mutant proteins was quantified by Western blot before the experiment and equal amounts of
788 SOX9 were detected (Supplemental Figure 2). After 48 hours, the whole-cell lysates were
789 extracted and incubated with 0.5 µl of Biotin-labeled probe (1000fM) for 20 min on ice in a
790 15µl reaction system as described previously (19), using Poly (dI:dC) as the unspecific
791 competitor. The 150-fold unlabeled DNA probes (150X) were incubated with cell lysate of
792 Cos-7 cells transfected with wild-type SOX9 protein. Samples were loaded onto native 6.5%
793 polyacrylamide gel and electrophoresed in 0.5xTBE at 180V for 1 h. The gel was transferred
794 to a nylon membrane at 100V for 30 min. The biotin-labeled DNA probes transferred to the
795 membrane were cross-linked for 10 min with a hand-held UV lamp and detected by
796 Chemiluminescence (BioRad, TY8836).

797 **Luciferase assay**

798 Luciferase assay was performed with a luciferase reporter (*Col11a2*-Luc) and various *SOX9*
799 expression constructs in Cos-7 cell cultures. To generate the *Col11a2*-Luc reporter, four
800 tandem copies of a canonical SOX9 binding motif derived from an enhancer region of the

801 mouse *Coll1a2* gene (named *Coll1a2* D/E) (19) was cloned into the luciferase reporter vector
802 pGL3Basic (Promega E1751). The sequence of this motif is listed in Supplemental Table 2.
803 Full-length wild-type *SOX9* and *SOX9* with variants were cloned into the pEGFP-C1
804 expression vector (Catalog #6084-1, Takara Bio Company). These overexpression constructs
805 were transfected into the Cos-7 cell line for 48 hours and equal amounts of protein were
806 harvested for Western Blotting analysis of SOX9. No obvious difference in SOX9 expression
807 was observed among wild-type and different *SOX9* variants (Supplemental Figure 3, A and B).
808 A standard curve was generated to determine the linear range of the SOX9-mediated reporter
809 transactivation and to optimize the reaction system (Supplemental Figure 3C). For each
810 independent experiment, Cos-7 cells were transfected with 400ng of *Coll1a2*-Luc reporter
811 plasmids, 50ng of various SOX9-expression vectors, and 5ng of Renilla luciferase control
812 reporter vectors. Cells were harvested 48h post-transfection for immediate luciferase activity
813 analysis using the Promega Dual-Luciferase Reporter Assay System (Promega E1910). The
814 Firefly luciferase activity was normalized to the Renilla luciferase activity. Three independent
815 experiments were performed with reproducible results.

816 **Half-life measurement**

817 The half-life of wild-type and variant SOX9 proteins were evaluated using a cycloheximide
818 (CHX) chase assay. Cos-7 cells were seeded into 6-well plates in DMEM containing 10% FBS
819 and transfected with 2 μ g of various *SOX9* expression constructs. 48 hours later, Cos-7 cells
820 were treated with 80 μ g/ml of CHX and were harvested at 0h, 1h, 2h, 4h, and 6h after treatment.
821 Cells were dissolved in absolute ethanol and harvested in ice-cold phosphate-buffered saline
822 (PBS, pH 7.4) by centrifuging at $2500 \times g$ for 2 min at 4 °C. Cell pellets were lysed in RIPA
823 lysis and extraction buffer (Thermo Scientific) and sonicated for 3×5 s on ice. Total protein
824 from the cell lysate was quantitated using the Pierce BCA protein assay kit (Thermo Scientific)
825 and analyzed by the standard Western blot assay. The membrane was blotted with a primary

826 anti-GFP tag antibody (Cell Signaling Technology, 2956T, 1:1000) and detected with a
827 secondary horseradish peroxidase-conjugated antibody (ab7090; Abcam; 1:5000).
828 Quantification of band intensity was conducted using Image Lab (BioRad). Three independent
829 experiments were performed with reproducible results.

830 **Generation of mouse models**

831 The *Sox9^{Asp272del}* mutant mouse was fortuitously isolated after pronuclear injection using an
832 oligo-dependent gene editing approach using a single CRISPR synthetic guide RNA 5'-
833 GTTCACCGATGTCCACGTCG-3' (Synthego) mixed with Alt-R S.p. HiFi Cas9 Nuclease
834 V3 protein (IDT, 1081060). For gene editing, a donor oligonucleotide 5'-
835 TCTGGCAGAGGGGGGCAGACAGCCCCCATCGACTTtCGtGAtGTaGAtATCtGcG
836 AACTGAGCAGCGACGTCATCTCCAACATTGAGACCTT-3', with phosphorothioate
837 linkages between the first three and last three nucleotides, was used to induce a specific edit to
838 model the Gly276Cys human mutation and add synonymous changes to include an EcoRV
839 restriction site for genotyping. The pronuclear injection was performed by the Mouse Genetic
840 Engineering Facility (UT-MGEF) at the University of Texas at Austin using standard protocols
841 (<https://www.biomedsupport.utexas.edu/transgenics>). Of the 123 implanted embryos from two
842 independent sessions, 3 mice were isolated at sexual maturity. Of these, 1 founder male
843 transmitted the *Sox9^{Asp272del}* allele. Locus-specific genotyping of the *Sox9^{Asp272del}* mutation was
844 performed using PCR primers 5'-GTCTTTCTCTTTTATGGCCTGC-3' and
845 5'TGGCAAGTATTGGTCAAACACTCA-3', followed by Sanger sequencing confirmation.
846 Heterozygous *Sox9^{Asp272del}* mutant mice are maintained in the C57B6/J background and have
847 been outcrossed to the C57BL/6J strain for over 10 generations. At each cross, we observe a
848 100% correspondence between genotype and phenotype.

849 **Analysis of mouse tissues**

850 Radiographs of the mouse skeleton were generated using a Kubtec DIGIMUS X-ray system
851 (Kubtec T0081B) with auto exposure under 25 kV. All radiographs were taken immediately
852 after the mice were euthanized to avoid the stiffness of the skeleton. Cobb's angle was measured
853 on high-resolution X-ray images with the software Surgimap (<https://www.surgimap.com>), as
854 previously described by (46). Measures of the length of the spine (T1-L6) and long bone (femur)
855 were performed on high-resolution X-ray images with ImageJ (<https://imagej.nih.gov/ij/>).

856 Mouse spine or tail tissues were harvested at P5, P60, and 6 months of age. Histological
857 analysis was performed on the distal tail or lumbar (L3-L5) spines fixed in 10% neutral buffered
858 formalin for 3 days at room temperature, followed by 3-5 days of decalcification in Formic
859 Acid Bone Decalcifier (Immunocal, StatLab). After decalcification, bones were embedded in
860 paraffin and sectioned at 5 μ m thickness. Alcian Blue Hematoxylin/Orange G (ABH/OG)
861 staining was performed following standard protocols (Center for Musculoskeletal Research,
862 University of Rochester). Immunohistochemical (IHC) analyses were performed on paraffin
863 sections with traditional antigen retrieval (COLII and COLX: 4 mg/ml pepsin in 0.01 N HCl
864 solution, 37°C water bath for 10 min; SOX9 and Collagen I: 10 μ g/ml proteinase K in 1x PBS,
865 room temperature for 10 min; TNX: 10 mM Tris-EDTA with 0.05% Triton-X-100, pH 9.0,
866 75°C water bath for 5 min) and colorimetric developed development methodologies with the
867 following primary antibodies: anti-SOX9 (EMD Millipore AB5535, 1:200), anti-COLII
868 (Thermo Scientific MS235B, 1:100), anti-COLX (Quartec, 1-CO097-05, 1:200), anti-COLI
869 (Abcam, ab138492, 1:1000), and anti-TNX (Santa Cruz Biotechnology sc-271594, 1:100).
870 Immunofluorescence (IF) staining was performed on paraffin sections as previously described
871 with modifications (67). Briefly, paraffin sections of P5 mouse tails were de-paraffinized and
872 incubated with 10 μ g/ml proteinase K in 1x PBS at room temperature for 10 min. Sections were

873 washed in 1xPBST and incubated with primary antibodies: anti-SOX9 (Chemicon AB5535,
874 1:200) and anti-TNX (Santa Cruz Biotechnology sc-271594, 1:100), and developed with
875 secondary antibody Alexa Flour 488 Goat anti Rabbit (A11034, 1:1500). Images were taken
876 using a Keyence BZ-X710 all-in-One fluorescence microscope and a Nikon Ti2E/CSU-W1
877 spinning disc confocal system. Quantification of SOX9 (+) cells was performed on high
878 resolution SOX9 IHC staining images with ImageJ. At least two sections were analyzed for
879 each mouse. At least three mice for each genotype were analyzed.

880 **MicroCT analysis**

881 MicroCT analysis was performed on the tails of P60 mice and P1 mouse pups. All samples
882 were fixed in 10% neutral-buffered formalin for 3 days at room temperature, thoroughly
883 washed, and scanned on a Bruker SkyScan 1276 (Bruker Corporation, Billerica,
884 Massachusetts). The tails were scanned at 50 kV and 200 μ A with a 0.25 mm Al filter, with a
885 3 μ m voxel size. The mouse pups were first proceeded for Alcian Blue/Alizarin Red skeletal
886 stain using standard acid-alcohol conditions and cleared in 1% KOH and Glycerol. These
887 embryos were scanned in glycerol at 50 kV and 100 μ A with a 0.5 mm Al filter, with a 3 μ m
888 voxel size. 3D Rendering and analysis was done using Bruker CTVOx and CTAn software.

889 **Costal chondrocytes isolation and maturation**

890 Murine costal chondrocytes were isolated as previously described by (67) with modifications.
891 Briefly, anterior rib cages and sterna were isolated from 5-day-old wild-type, *Sox9^{del/+}* and
892 *Sox9^{del/del}* pups with the soft tissue removed. Rib cages were digested in 2mg/ml Pronase
893 (Roche) solution at 37°C for 1 hour with constant agitation, followed by 1-hour digestion in
894 3mg/ml collagenase D (Roche) solution in high-glucose Dulbecco's modified Eagle's medium
895 (DMEM, Gibco) at 37°C. The rib cages were then transferred into a petri dish and digested in
896 collagenase D (3 mg/ml in high-glucose DMEM) for 4 to 6 hours. Murine costal chondrocyte

897 cell suspensions were filtered through 40µm filters and seeded at a density of 200,000 cells per
898 well in 24-well tissue culture plates. Cells were matured with maturation medium
899 [highglucose DMEM supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin,
900 and 50µg/ml ascorbic acid (Sigma, A4403)] for 10 days with changing of the medium in every
901 two days. After 10 days of maturation, cells were fixed with 500µl of 10% Formaldehyde at
902 RT for 20min, thoroughly washed with PBS, and incubated with Alcian Blue staining solution
903 (Sigma, B8438) or anti-SOX9 antibody (EMD Millipore AB5535, 1:400) overnight at room
904 temperature or 4°C. The next day Alcian Blue stained cells were washed with deionized water
905 and air-dried overnight. The SOX9 antibody-stained cells were developed with a secondary
906 antibody Alexa Flour 488 Goat anti Rabbit (A11034, 1:1500).

907 **RNA isolation and real-time RT-PCR**

908 RNA was isolated from primary costal chondrocytes without maturation with a QIAGEN
909 RNeasy mini kit (QIAGEN 74104). Reverse transcription was performed using 500 ng total
910 RNA with an iScript cDNA synthesis kit (Bio-Rad 1708840). Real-time RT-PCR (qPCR)
911 analyses were performed as previously described by (67). Gene expression was normalized to
912 b-actin mRNA and relative expression was calculated using the 2-($\Delta\Delta C_t$) method. The mouse-
913 specific primers were used to quantify gene expression (Supplemental Table 1). Real-time RT-
914 PCR efficiency was optimized and melting curve analyses of products were performed to
915 ensure reaction specificity.

916 **Protein extraction and western blot of the primary cells**

917 Total proteins were extracted from primary costal chondrocytes without maturation with
918 protein extraction buffer [50mM HEPES, 1.5mM EDTA (pH 8.0), 150mM NaCl, 10%
919 glycerol, 1% Triton X-100] supplemented with protease and phosphatase inhibitors (Roche).
920 10mg of protein from each sample was resolved by 4–15% SDS-polyacrylamide gel

921 electrophoresis and transferred to the nitrocellulose membranes. Western blots were then
922 blocked with LI-COR blocking buffer and incubated overnight with primary antibodies anti-
923 SOX9 (EMD Millipore AB5535, 1:1000) and anti-GAPDH (Cell Signaling, #2118, 1:2500) at
924 4°C with gentle rocking. The next day western blots were detected with the LI-COR Odyssey
925 infrared imaging system. Quantification of band intensity was conducted with ImageJ. Three
926 independent experiments were performed with reproducible results.

927 **RNA-sequencing and data analysis**

928 RNA-sequencing was performed on costal chondrocytes isolated from P5 *Sox9^{del/+}* mice and
929 *Sox9^{del/del}* mice. Briefly, anterior rib cages and sterna were isolated from P5 pups, digested in
930 2mg/ml Pronase solution at 37°C for 1 hour with constant agitation, followed by 1-hour
931 digestion in 3mg/ml collagenase D solution in 1XPBS. Cells were disassociated, thoroughly
932 washed in 1XPBS and filtered through a 40µm cell strainer. Cells were pelleted by centrifuging
933 at 300 × g for 4 min at room temperature. RNA was isolated with a QIAGEN RNeasy mini kit
934 (QIAGEN 74104).

935 Library preparation, RNA sequencing, and bioinformatics analysis were performed by
936 Novogene Co., Ltd. Messenger RNA was purified from total RNA using poly-T oligo-attached
937 magnetic beads. After fragmentation, the first strand of cDNA was synthesized using random
938 hexamer primers, followed by the second strand of cDNA synthesis. The library was examined
939 with Qubit and real-time PCR for quantification and a bioanalyzer for size distribution
940 detection. Quantified libraries were pooled and sequenced on Illumina platforms and pairedend
941 reads were generated. Raw data in fastq format were firstly processed through in-house Perl
942 scripts and clean reads were obtained. Reference genome and gene model annotation files were
943 downloaded from the genome website directly. Index of the reference genome was built using
944 Hisat2 v2.0.5 and paired-end clean reads were aligned to the reference genome using Hisat2

945 v2.0.5. featureCounts v1.5.0-p3 was used to count the reads numbers mapped to each gene.
946 FPKM of each gene was calculated based on the length of the gene and the reads count mapped
947 to this gene. Differential expression analysis was performed using the DESeq2 R package
948 (1.20.0). The resulting P-values were adjusted using Benjamini and Hochberg's approach for
949 controlling the false discovery rate. Genes with an adjusted P-value ≤ 0.05 found by DESeq2
950 were assigned as differentially expressed. Gene Ontology (GO) enrichment analysis of
951 differentially expressed genes was implemented by the clusterProfiler R package, in which gene
952 length bias was corrected. GO terms with corrected P value less than 0.05 were considered
953 significantly enriched in differential expressed genes.

954 **Statistics**

955 Statistical analyses were performed in GraphPad Prism 9.1.2 (GraphPad Software Inc,
956 SanDiego, CA) or SPSS version 15.0 (SPSS). For luciferase assay, half-life analysis, Cobb
957 angle, and gene expression analysis to compare two or more experimental groups, 2-tailed
958 Student's t-test and Welch one-way ANOVA followed by Turkey's multiple comparison test
959 were applied when appropriate. A p-value of less than 0.05 is considered statistically
960 significant.

961

962 **Study approval**

963 This study was approved by the Institutional Review Board of Peking Union Medical College
964 Hospital (JS-2364). Written informed consent was obtained from each patient or legal
965 guardian of the patient. All mouse studies and procedures were approved by the Animal
966 Studies Committee at the University of Texas at Austin.

967

968 **Statement**

969 The patient ID is a unique research identifier that cannot be linked back to the original patients
970 outside of the research group. Medical history details have also been removed to protect the
971 patients' privacy.

972

973 **Data availability**

974 Data are available from the corresponding author upon reasonable request.

975 **Author contributions**

976 N.W., R.S.G., L.W., Z.L. and S.Z. conceptualized the project. L.W., Z.L., S.Z. L.Z., Xiaoxin.L.,
977 N.W. and R.S.G. designed the study. L.W., S.Z., Z.L., C.Q., B.T., G.H., R.S.G. L.L. Xinyu.L.
978 and L.Z. performed the experiments. S.Z., L.W., Z.L., K.X., C.M.K, Xiaoxin.L., R.S.G., H.G.
979 and L.L. validated the data. N.W., S.Z., L.W., Z.L., H.G., S.Y., V.A., S.M., S.W., Y.N., R.S.G.
980 and T.J.Z. analyzed the data. L.W., S.Z., Z.L., K.X., N.W. and R.S.G. wrote the manuscript.
981 S.Z., Z.L., L.W., K.X., N.W., Z.W., C.Q., Xinyu.L. and R.S.G. critically revised the
982 manuscript. Z.L., R.S.G., N.W. and Z.W. supervised the work. All authors have read and
983 approved the final submitted manuscript. The first authorship is shared by Z.L., L.W., S.Z., and
984 K.X. The order was determined based on their respective contributions and efforts to the study.
985

986 **Acknowledgments**

987 We thank Dr. Yunjia Wang at the Department of Spine and Orthopaedics in Xiangya
988 Hospital/Central South University, and Ms. Karagan Day at the Department of Pediatrics in
989 Dell Medical School of the University of Texas at Austin for their supporting work in mouse

990 husbandry and X-ray image taking. We also thank Nanjing Geneseeq Technology Inc. for the
991 technical help in sequencing and Ekitech Technology Inc. for the technical support in database
992 and data management.

993

994 **Funding**

995 This research was funded in part by the National Natural Science Foundation of China
996 (81930068 to Z.W., 2102522 to L.W., 82072391 to N.W., 881972037 and 82172382 to J.Z.,
997 and 81874022 and 82172483 to X.L.), Beijing Natural Science Foundation (JQ20032 to N.W.),
998 CAMS Innovation Fund for Medical Sciences (CIFMS, 2021-I2M-1-051 to J.Z. and N.W.,
999 2021-I2M-1-052 to Z.W., 2020-I2M-C&T-B-030 to J.Z.), National High Level Hospital
1000 Clinical Research Funding (2022-PUMCH-D-007 to J.Z. and N.W., 2022-PUMCH-C-033 to
1001 N.W.), National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National
1002 Institutes of Health under Award (R01AR072009 to R.S.G., K99AR077090 to Z.L.), Shandong
1003 Natural Science Foundation (ZR202102210113 to L.W.), and the Non-profit Central Research
1004 Institute Fund of Chinese Academy of Medical Sciences (No. 2019PT320025 to N.W.).

1005

1006

1007 **SUPPLEMENTAL FIGURE LEGENDS**

1008 **Supplemental Figure 1. The 3D structures of SOX9 are predicted by AlphaFold.** (A) A
1009 model of human SOX9 was built by AlphaFold (<https://alphafold.ebi.ac.uk/>). (B) Ile73 is
1010 predicted to be important for stabilizing alpha-helical interactions. (C) Met113 is predicted to
1011 stabilize alpha-helical interactions through a single hydrogen bond with Gln117 and two
1012 hydrogen bonds with Aan110. (D) Ala133 is predicted to stabilize alpha-helical interactions by
1013 a hydrogen bond with Ser136. (E) Gly276 is predicted to hydrogen bond with Asp274. Asp272
1014 is also predicted to hydrogen bond with Asp274 by stabilizing an alpha-helical structure.

1015

1016 **Supplemental Figure 2. Equal amounts of SOX9 proteins were used for the EMSA assay.**

1017 (A) Western blotting of anti-GFP was performed on total protein extracted from blank Cos-7
1018 cells (Blank), Cos-7 cells transfected with empty EGFP expression vectors (Control), wild-
1019 type SOX9 (WT), or Ile73Thr, Met113Leu, and Ala133Gly SOX9 variants that were cloned
1020 into the EGFP expression vectors at 48 hours post-transfection. GAPDH is used as a loading
1021 control. No obvious changes in expression were observed among wild-type and variant SOX9
1022 proteins. (B) Quantification analysis shows that comparable amounts of SOX9 were detected
1023 among wild-type and various SOX9 variant proteins. Bars are plotted with mean and SD. Each
1024 dot represents one experiment analyzed. The statistical difference is evaluated by one-way
1025 ANOVA followed by Tukey's multiple comparison test. ns: not significant. (n=3 experiments.)

1026

1027 **Supplemental Figure 3. Optimization of the luciferase assay.** (A) Western blotting was
1028 performed on total protein extracted from blank Cos-7 cells (Blank), Cos-7 cells transfected
1029 with wild-type SOX9 construct (Wild type), or Ile73Thr, Gly276Cys, Met113Leu, Ala133Gly,
1030 and Asp276Del SOX9 variants at 48 hours post-transfection. GAPDH is used as a loading

1031 control. No obvious changes in expression were observed among wild-type and variant SOX9
1032 proteins. **(B)** Quantification analysis shows that comparable amounts of SOX9 were detected
1033 among wild-type and various SOX9 variant proteins. Bars are plotted with mean and SD. Each
1034 dot represents one experiment analyzed. The statistical difference is evaluated by one-way
1035 ANOVA followed by Tukey's multiple comparison test. ns: not significant. (n=3 experiments.)
1036 **(C)** A standard curve was generated to optimize the transfection dose for the luciferase assays.
1037 SOX9-expression plasmids were diluted to a gradient of concentration with the final amount
1038 from 10^{-4} to 10^6 ng. Relative luciferase activity was normalized to the Renilla internal control.
1039 The linear range of the SOX9-mediated reporter transactivation is between 1ng-100ng. 50ng
1040 of SOX9-expression plasmids was selected for luciferase assays shown in Figure 2B. n=3
1041 experiments.

1042

1043 **Supplemental Figure 4. Expression of extracellular matrix components in P5 mouse tail**
1044 **sections. (A-B'')** Representative Alcian Blue Hematoxylin /Orange G (ABH/OG) staining
1045 **(AA'')** and IHC staining of SOX9 **(B-B'')** on unwedged IVD in tail sections of P5 Sox9del/del
1046 mutant mice. The endplate is indicated with a dot line and a vertical bar in **(A')** and **(B')**. The
1047 boundary between inner and outer annulus fibrosus is indicated with a dot-line in **(A'')** and
1048 **(B'')**. (n=3.) C-H, IHC analysis of COLII **(C-E)** and COLX **(F-H)** on tail sections of P5
1049 wildtype, Sox9^{del/+}, and Sox9^{del/del} mice. n=3 for each genotype. Scale bars: 100µm. EP:
1050 endplate; GP-p: proliferative growth plate; GP-h: hypertrophic growth plate; AF-i: inner
1051 annulus fibrosus; AF-o: outer annulus fibrosus.

1052

1053 **Supplemental Figure 5. Assessment of skeletal development in Sox9 loss of function**
1054 **mutant mice. (A-C)** Representative skeletal preps of Cre(-) wild-type **(A)**, heterozygous
1055 *Col2a1-Cre; Sox9^{flox/+}* mutant **(B)**, and compound heterozygous *Col2a1-Cre; Sox9^{flox/del}* mutant

1056 mice (C) at P1. (D-F) Representative MicroCT images of Cre(-) wild-type (D), heterozygous
1057 *Col2a1-Cre; Sox9^{lox/+}* mutant (E), and compound heterozygous *Col2a1-Cre; Sox9^{lox/del}* mutant
1058 mice (F) at P1. n=4 for each genotype. Scale bar: 1mm.

1059

1060 **Supplemental Figure 6. Young adult *Sox9^{del/del}* mice display mild rib cage deformities.**

1061 (A-C) Representative sagittal X-ray images of wild-type (A), *Sox9^{del/+}* (B), and *Sox9^{del/del}* mice
1062 (C) at P60. Red arrows indicate the curvature of the distal ribs (C). n=4 for wild-type mice; 2
1063 males, 2 females. n=8 for *Sox9^{del/+}* mice; 5 males, 3 females. n=7 for *Sox9^{del/del}* mice; 4 males,
1064 3 females. Scale bar: 10mm.

1065

1066 **Supplemental Figure 7. Mature adult *Sox9^{del/del}* mice display rib cage deformities and**

1067 **impaired ossification in the endplate of the intervertebral discs.** (A-E) Additional sagittal
1068 X-ray images of wild-type (A), *Sox9^{del/+}* (B), and *Sox9^{del/del}* mice (C-E) at 6 months. Red arrows
1069 indicate the bending of the sternums (B-D) or the curvature of the distal ribs I. (F-J') Additional
1070 ABH/OG staining of lumbar IVDs (L3/4 or L4/5) of wild-type (F, F'), *Sox9^{del/+}* (G, G') and
1071 *Sox9^{del/del}* (H-J') mice at 6 months. Wild-type and *Sox9^{del/+}* mice consistently showed
1072 ossification within the endplate at 6 months (yellow arrows, F' and G'). On the contrary,
1073 *Sox9^{del/del}* mice showed reduced endplate ossification (yellow arrow, J') or persistency of
1074 hypertrophic chondrocyte-like cells within the endplate (yellow asterisks, H', I'). n=3 for each
1075 genotype. Scale bars: 10mm in A; 100µm in F-F'. AF: annulus fibrosus; EP: endplate; GP:
1076 growth plate; NP: nucleus pulposus.

1077

1078 **Supplemental Figure 8. SOX9 protein expression in costal chondrocytes.** (A)

1079 Representative Western blot image of SOX9 performed on P5 costal chondrocytes isolated

1080 from three different genotypes of mice. GAPDH is used as a loading control (n=3 experiments).

1081 **(B)** Quantification analysis shows that comparable amounts of SOX9 protein were detected

1082 among three genotypes. Bars are plotted with mean and 95%CI. Each dot represents one

1083 experiment analyzed. The statistical difference is evaluated by one-way ANOVA followed by

1084 Tukey's multiple comparison test. ns: not significant (n=3 experiments).

1085

1086 **Supplemental Table 1.** Primers used for amplification of the DNA segments containing the

1087 candidate *SOX9* variants and for RT-PCR quantification.

1088 **Supplemental Table 2.** Sequences of the SOX9 binding motifs used for EMSA and luciferase

1089 assay.

1090 **Supplemental Table 3.** Differential gene expression analysis of primary costal chondrocytes

1091 derived from *Sox9^{del/+}* and *Sox9^{del/del}* mutant mice.

1092 **Supplemental Table 4.** GO-terms associated with differential gene expression analysis of

1093 primary costal chondrocytes derived from *Sox9^{del/+}* and *Sox9^{del/del}* mutant mice.

1094

1095 **Table 1.** Clinical and genetic features of the four probands

ID	RDD2003P0397	SCO2003P0412	SCO2003P0060	SCO2003P1898
Variant information				
HGVS	c.337A>C (p.Met113Leu)	c.398C>G (p.Ala133Gly)	c.218T>C (p.Ile73Thr)	c.826G>T (p.Gly276Cys)
Origin	<i>de novo</i>	Unknown	<i>de novo</i>	<i>de novo</i>
Domain	HMG	HMG	DIM	TAM
CADD	27.3	26.5	24.1	29.6
Skeleton, joints and limbs				
Scoliosis	-	+	+	+
Kyphosis	+	-	+	-
Lordosis	+	-	-	-
Vertebral malformation	Fusion of cervical vertebrae	of L2 vertebra	wedged T6 vertebra	wedged T6 vertebra Fusion of thoracic vertebrae
Other skeletal deformity	Hypoplastic scapulae	Brachydactyly	Hypoplastic scapulae, Short stature	Spinal bifida occulta, Clinodactyly

1096

1097 *Abbreviations: DIM: dimerization domain; HMG: high mobility group domain; TAM:*

1098 *transactivation middle domain.*

1099

1100 REFERENCES

- 1101 1. Lefebvre V. Roles and regulation of SOX transcription factors in skeletogenesis. *Curr*
1102 *Top Dev Biol.* 2019;133:171-93.
- 1103 2. Lefebvre V, and Dvir-Ginzberg M. SOX9 and the many facets of its regulation in the
1104 chondrocyte lineage. *Connect Tissue Res.* 2017;58(1):2-14.
- 1105 3. Akiyama H, Chaboissier MC, Martin JF, Schedl A, and de Crombrughe B. The
1106 transcription factor Sox9 has essential roles in successive steps of the chondrocyte
1107 differentiation pathway and is required for expression of Sox5 and Sox6. *Genes Dev.*
1108 2002;16(21):2813-28.
- 1109 4. Barrionuevo F, Taketo MM, Scherer G, and Kispert A. Sox9 is required for notochord
1110 maintenance in mice. *Dev Biol.* 2006;295(1):128-40.
- 1111 5. Sugimoto Y, Takimoto A, Akiyama H, Kist R, Scherer G, Nakamura T, et al.
1112 Scx+/Sox9+ progenitors contribute to the establishment of the junction between
1113 cartilage and tendon/ligament. *Development.* 2013;140(11):2280-8.
- 1114 6. Henry SP, Liang S, Akdemir KC, and de Crombrughe B. The postnatal role of Sox9
1115 in cartilage. *J Bone Miner Res.* 2012;27(12):2511-25.
- 1116 7. Tsingas M, Ottone OK, Haseeb A, Barve RA, Shapiro IM, Lefebvre V, et al. Sox9
1117 deletion causes severe intervertebral disc degeneration characterized by apoptosis,
1118 matrix remodeling, and compartment-specific transcriptomic changes. *Matrix Biol.*
1119 2020;94:110-33.
- 1120 8. Haseeb A, and Lefebvre V. The SOXE transcription factors-SOX8, SOX9 and SOX10-
1121 share a bi-partite transactivation mechanism. *Nucleic Acids Res.* 2019;47(13):6917-31.
- 1122 9. Oh CD, Maity SN, Lu JF, Zhang J, Liang S, Coustry F, et al. Identification of SOX9
1123 interaction sites in the genome of chondrocytes. *PLoS One.* 2010;5(4):e10113.

- 1124 10. Barrionuevo F, and Scherer G. SOX E genes: SOX9 and SOX8 in mammalian testis
1125 development. *Int J Biochem Cell Biol.* 2010;42(3):433-6.
- 1126 11. Zhao L, Li G, and Zhou GQ. SOX9 directly binds CREB as a novel synergism with the
1127 PKA pathway in BMP-2-induced osteochondrogenic differentiation. *J Bone Miner Res.*
1128 2009;24(5):826-36.
- 1129 12. Miyake A, Kou I, Takahashi Y, Johnson TA, Ogura Y, Dai J, et al. Identification of a
1130 susceptibility locus for severe adolescent idiopathic scoliosis on chromosome 17q24.3.
1131 *PLoS One.* 2013;8(9):e72802.
- 1132 13. Takeda K, Kou I, Otomo N, Grauers A, Fan YH, Ogura Y, et al. A multiethnic meta-
1133 analysis defined the association of rs12946942 with severe adolescent idiopathic
1134 scoliosis. *J Hum Genet.* 2019;64(5):493-8.
- 1135 14. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, et al. Autosomal sex reversal
1136 and campomelic dysplasia are caused by mutations in and around the SRY-related gene
1137 SOX9. *Cell.* 1994;79(6):1111-20.
- 1138 15. Foster JW, Dominguez-Steglich MA, Guioli S, Kwok C, Weller PA, Stevanovic M, et
1139 al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-
1140 related gene. *Nature.* 1994;372(6506):525-30.
- 1141 16. Houston CS, Opitz JM, Spranger JW, Macpherson RI, Reed MH, Gilbert EF, et al. The
1142 campomelic syndrome: review, report of 17 cases, and follow-up on the currently 17-
1143 year-old boy first reported by Maroteaux et al in 1971. *Am J Med Genet.* 1983;15(1):3-
1144 28.
- 1145 17. Bernard P, Tang P, Liu S, Dewing P, Harley VR, and Vilain E. Dimerization of SOX9
1146 is required for chondrogenesis, but not for sex determination. *Hum Mol Genet.*
1147 2003;12(14):1755-65.

- 1148 18. Lewandoski M, Meyers EN, and Martin GR. Analysis of Fgf8 gene function in
1149 vertebrate development. *Cold Spring Harb Symp Quant Biol.* 1997;62:159-68.
- 1150 19. Sock E, Pagon RA, Keymolen K, Lissens W, Wegner M, and Scherer G. Loss of DNA-
1151 dependent dimerization of the transcription factor SOX9 as a cause for campomelic
1152 dysplasia. *Hum Mol Genet.* 2003;12(12):1439-47.
- 1153 20. Leipoldt M, Erdel M, Bien-Willner GA, Smyk M, Theurl M, Yatsenko SA, et al. Two
1154 novel translocation breakpoints upstream of SOX9 define borders of the proximal and
1155 distal breakpoint cluster region in campomelic dysplasia. *Clin Genet.* 2007;71(1):67-
1156 75.
- 1157 21. Velagaleti GV, Bien-Willner GA, Northup JK, Lockhart LH, Hawkins JC, Jalal SM, et
1158 al. Position effects due to chromosome breakpoints that map approximately 900 Kb
1159 upstream and approximately 1.3 Mb downstream of SOX9 in two patients with
1160 campomelic dysplasia. *Am J Hum Genet.* 2005;76(4):652-62.
- 1161 22. Pfeifer D, Kist R, Dewar K, Devon K, Lander ES, Birren B, et al. Campomelic
1162 dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9:
1163 evidence for an extended control region. *Am J Hum Genet.* 1999;65(1):111-24.
- 1164 23. Bi W, Huang W, Whitworth DJ, Deng JM, Zhang Z, Behringer RR, et al.
1165 Haploinsufficiency of Sox9 results in defective cartilage primordia and premature
1166 skeletal mineralization. *Proc Natl Acad Sci U S A.* 2001;98(12):6698-703.
- 1167 24. Au TYK, Yip RKH, Wynn SL, Tan TY, Fu A, Geng YH, et al. Hypomorphic and
1168 dominant-negative impact of truncated SOX9 dysregulates Hedgehog-Wnt signaling,
1169 causing campomelia. *Proc Natl Acad Sci U S A.* 2023;120(1):e2208623119.
- 1170 25. Macpherson RI, Skinner SA, and Donnemfeld AE. Acampomelic campomelic
1171 dysplasia. *Pediatr Radiol.* 1989;20(1-2):90-3.

- 1172 26. von Bohlen AE, Bohm J, Pop R, Johnson DS, Tolmie J, Stucker R, et al. A mutation
1173 creating an upstream initiation codon in the SOX9 5' UTR causes acampomelic
1174 campomelic dysplasia. *Mol Genet Genomic Med.* 2017;5(3):261-8.
- 1175 27. Vivekanandan S, Moovarkumudalvan B, Lescar J, and Kolatkar PR. Crystallization and
1176 X-ray diffraction analysis of the HMG domain of the chondrogenesis master regulator
1177 Sox9 in complex with a ChIP-Seq-identified DNA element. *Acta Crystallogr F Struct
1178 Biol Commun.* 2015;71(Pt 11):1437-41.
- 1179 28. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, et al. SOX9 directly
1180 regulates the type-II collagen gene. *Nat Genet.* 1997;16(2):174-8.
- 1181 29. Lefebvre V, Zhou G, Mukhopadhyay K, Smith CN, Zhang Z, Eberspaecher H, et al.
1182 An 18-base-pair sequence in the mouse proalpha1(II) collagen gene is sufficient for
1183 expression in cartilage and binds nuclear proteins that are selectively expressed in
1184 chondrocytes. *Mol Cell Biol.* 1996;16(8):4512-23.
- 1185 30. Bridgewater LC, Lefebvre V, and de Crombrughe B. Chondrocyte-specific enhancer
1186 elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer. *J Biol
1187 Chem.* 1998;273(24):14998-5006.
- 1188 31. McDowall S, Argentaro A, Ranganathan S, Weller P, Mertin S, Mansour S, et al.
1189 Functional and structural studies of wild type SOX9 and mutations causing campomelic
1190 dysplasia. *J Biol Chem.* 1999;274(34):24023-30.
- 1191 32. Csukasi F, Duran I, Zhang W, Martin JH, Barad M, Bamshad M, et al. Dominant-
1192 negative SOX9 mutations in campomelic dysplasia. *Hum Mutat.* 2019;40(12):2344-52.
- 1193 33. Schock EN, and LaBonne C. Sorting Sox: Diverse Roles for Sox Transcription Factors
1194 During Neural Crest and Craniofacial Development. *Front Physiol.* 2020;11:606889.
- 1195 34. Unger S, Scherer G, and Superti-Furga A. In: Adam MP, Everman DB, Mirzaa GM,
1196 Pagon RA, Wallace SE, Bean LJH, et al. eds. *GeneReviews((R))*. Seattle (WA); 1993.

- 1197 35. Wu N, Wang L, Hu J, Zhao S, Liu B, Li Y, et al. A Recurrent Rare SOX9 Variant
1198 (M469V) is Associated with Congenital Vertebral Malformations. *Curr Gene Ther.*
1199 2019;19(4):242-7.
- 1200 36. Calvache CA, Vasquez EC, Romero VI, Hosomichi K, and Pozo JC. Novel SRY-box
1201 transcription factor 9 variant in campomelic dysplasia and the location of missense and
1202 nonsense variants along the protein domains: A case report. *Front Pediatr.*
1203 2022;10:975947.
- 1204 37. Geraldo MT, Valente GT, Nakajima RT, and Martins C. Dimerization and
1205 Transactivation Domains as Candidates for Functional Modulation and Diversity of
1206 Sox9. *PLoS One.* 2016;11(5):e0156199.
- 1207 38. Staffler A, Hammel M, Wahlbuhl M, Bidlingmaier C, Flemmer AW, Pagel P, et al.
1208 Heterozygous SOX9 mutations allowing for residual DNA-binding and transcriptional
1209 activation lead to the acampomelic variant of campomelic dysplasia. *Hum Mutat.*
1210 2010;31(6):E1436-44.
- 1211 39. Wada Y, Nishimura G, Nagai T, Sawai H, Yoshikata M, Miyagawa S, et al. Mutation
1212 analysis of SOX9 and single copy number variant analysis of the upstream region in
1213 eight patients with campomelic dysplasia and acampomelic campomelic dysplasia. *Am*
1214 *J Med Genet A.* 2009;149A(12):2882-5.
- 1215 40. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical
1216 application of whole-exome sequencing across clinical indications. *Genet Med.*
1217 2016;18(7):696-704.
- 1218 41. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
1219 guidelines for the interpretation of sequence variants: a joint consensus
1220 recommendation of the American College of Medical Genetics and Genomics and the
1221 Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-24.

- 1222 42. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly
1223 accurate protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583-9.
- 1224 43. Huang YH, Jankowski A, Cheah KS, Prabhakar S, and Jauch R. SOXE transcription
1225 factors form selective dimers on non-compact DNA motifs through multifaceted
1226 interactions between dimerization and high-mobility group domains. *Sci Rep*.
1227 2015;5:10398.
- 1228 44. Bridgewater LC, Walker MD, Miller GC, Ellison TA, Holsinger LD, Potter JL, et al.
1229 Adjacent DNA sequences modulate Sox9 transcriptional activation at paired Sox sites
1230 in three chondrocyte-specific enhancer elements. *Nucleic Acids Res*. 2003;31(5):1541-
1231 53.
- 1232 45. Giampietro PF, Raggio CL, Blank RD, McCarty C, Broeckel U, and Pickart MA.
1233 Clinical, genetic and environmental factors associated with congenital vertebral
1234 malformations. *Mol Syndromol*. 2013;4(1-2):94-105.
- 1235 46. Cobb JR. Scoliosis; quo vadis. *J Bone Joint Surg Am*. 1958;40-A(3):507-10.
- 1236 47. Abid I, Ewais MM, Marranca J, and Jaroszewski DE. Pectus Excavatum: A Review of
1237 Diagnosis and Current Treatment Options. *J Am Osteopath Assoc*. 2017;117(2):106-
1238 13.
- 1239 48. David VL. Current Concepts in the Etiology and Pathogenesis of Pectus Excavatum in
1240 Humans-A Systematic Review. *J Clin Med*. 2022;11(5).
- 1241 49. Haseeb A, Kc R, Angelozzi M, de Charleroy C, Rux D, Tower RJ, et al. SOX9 keeps
1242 growth plates and articular cartilage healthy by inhibiting chondrocyte
1243 dedifferentiation/osteoblastic redifferentiation. *Proc Natl Acad Sci U S A*. 2021;118(8).
- 1244 50. Smith LJ, Nerurkar NL, Choi KS, Harfe BD, and Elliott DM. Degeneration and
1245 regeneration of the intervertebral disc: lessons from development. *Dis Model Mech*.
1246 2011;4(1):31-41.

- 1247 51. Zhao CQ, Wang LM, Jiang LS, and Dai LY. The cell biology of intervertebral disc
1248 aging and degeneration. *Ageing Res Rev.* 2007;6(3):247-61.
- 1249 52. Hong X, Liu W, Song R, Shah JJ, Feng X, Tsang CK, et al. SOX9 is targeted for
1250 proteasomal degradation by the E3 ligase FBW7 in response to DNA damage. *Nucleic*
1251 *Acids Res.* 2016;44(18):8855-69.
- 1252 53. Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, et al. Inhibition of
1253 eukaryotic translation elongation by cycloheximide and lactimidomycin. *Nat Chem*
1254 *Biol.* 2010;6(3):209-17.
- 1255 54. Ghosh S, Laha M, Mondal S, Sengupta S, and Kaplan DL. In vitro model of
1256 mesenchymal condensation during chondrogenic development. *Biomaterials.*
1257 2009;30(33):6530-40.
- 1258 55. Hu G, Codina M, and Fisher S. Multiple enhancers associated with ACAN suggest
1259 highly redundant transcriptional regulation in cartilage. *Matrix Biol.* 2012;31(6):328-
1260 37.
- 1261 56. Leung VY, Gao B, Leung KK, Melhado IG, Wynn SL, Au TY, et al. SOX9 governs
1262 differentiation stage-specific gene expression in growth plate chondrocytes via direct
1263 concomitant transactivation and repression. *PLoS Genet.* 2011;7(11):e1002356.
- 1264 57. Sekido R, and Lovell-Badge R. Sex determination involves synergistic action of SRY
1265 and SF1 on a specific Sox9 enhancer. *Nature.* 2008;453(7197):930-4.
- 1266 58. Taniguchi Y, Kawata M, Ho Chang S, Mori D, Okada K, Kobayashi H, et al. Regulation
1267 of Chondrocyte Survival in Mouse Articular Cartilage by p63. *Arthritis Rheumatol.*
1268 2017;69(3):598-609.
- 1269 59. Nishimori S, Lai F, Shiraishi M, Kobayashi T, Kozhemyakina E, Yao TP, et al. PTHrP
1270 targets HDAC4 and HDAC5 to repress chondrocyte hypertrophy. *JCI Insight.*
1271 2019;4(5).

- 1272 60. Burch GH, Gong Y, Liu W, Dettman RW, Curry CJ, Smith L, et al. Tenascin-X
1273 deficiency is associated with Ehlers-Danlos syndrome. *Nat Genet.* 1997;17(1):104-8.
- 1274 61. Mao JR, Taylor G, Dean WB, Wagner DR, Afzal V, Lotz JC, et al. Tenascin-X
1275 deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen
1276 deposition. *Nat Genet.* 2002;30(4):421-5.
- 1277 62. Liu Z, Easson GWD, Zhao J, Makki N, Ahituv N, Hilton MJ, et al. Dysregulation of
1278 STAT3 signaling is associated with endplate-oriented herniations of the intervertebral
1279 disc in *Adgrg6* mutant mice. *PLoS Genet.* 2019;15(10):e1008096.
- 1280 63. Liu Z, Hussien AA, Wang Y, Heckmann T, Gonzalez R, Karner CM, et al. An adhesion
1281 G protein-coupled receptor is required in cartilaginous and dense connective tissues to
1282 maintain spine alignment. *Elife.* 2021;10.
- 1283 64. Kou I, Takahashi Y, Johnson TA, Takahashi A, Guo L, Dai J, et al. Genetic variants in
1284 GPR126 are associated with adolescent idiopathic scoliosis. *Nat Genet.*
1285 2013;45(6):676-9.
- 1286 65. Zhao S, Zhang Y, Chen W, Li W, Wang S, Wang L, et al. Diagnostic yield and clinical
1287 impact of exome sequencing in early-onset scoliosis (EOS). *J Med Genet.*
1288 2021;58(1):41-7.
- 1289 66. Chen N, Zhao S, Jolly A, Wang L, Pan H, Yuan J, et al. Perturbations of genes essential
1290 for Mullerian duct and Wolffian duct development in Mayer-Rokitansky-Kuster-
1291 Hauser syndrome. *Am J Hum Genet.* 2021;108(2):337-45.
- 1292 67. Liu Z, Chen J, Mirando AJ, Wang C, Zuscik MJ, O'Keefe RJ, et al. A dual role for
1293 NOTCH signaling in joint cartilage maintenance and osteoarthritis. *Sci Signal.*
1294 2015;8(386):ra71.
- 1295